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Nanotheranostics, which combines optical multiplexed disease detection with
therapeutic monitoring in a single modality, has the potential to propel the
field of nanomedicine toward genuine personalized medicine. Currently
employed mainstream modalities using gold nanoparticles (AuNPs) in
diagnosis and treatment are limited by a lack of specificity and potential
issues associated with systemic toxicity. Light-mediated nanotheranostics
offers a relatively non-invasive alternative for cancer diagnosis and treatment
by using AuNPs of specific shapes and sizes that absorb near infrared (NIR)
light, inducing plasmon resonance for enhanced tumor detection and
generating localized heat for tumor ablation. Over the last decade, significant
progress has been made in the field of nanotheranostics, however the main
biological and translational barriers to nanotheranostics leading to a new
paradigm in anti-cancer nanomedicine stem from the molecular complexities
of cancer and an incomplete mechanistic understanding of utilization of
Au-NPs in living systems. This work provides a comprehensive overview on
the biological, physical and translational barriers facing the development of
nanotheranostics. It will also summarise the recent advances in engineering
specific AuNPs, their unique characteristics and, importantly, tunability to
achieve the desired optical/photothermal properties.
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1. Introduction
Novel nanoparticle (NP) engineering has re-
cently emerged as a key innovative driver
in combining diagnosis and treatment
into a “unified” one-step platform known
as “nanotheranostics.”[1,2] The application
of this approach in cancer management
is still in its infancy but promises to
have significant potential, since state-of-
the-art optical technologies coupled with
treatment modalities are expected to play
an increasingly important role in disease
management.[3] However, more work is re-
quired to elucidate many of the mecha-
nisms associated with its use in medicine.
An innovative formulation, such as a sin-
gle agent or NP which can integrate the
functions of imaging, targeting, and ther-
apeutics in a single vehicle, is known as
a theranostic agent.[4] A theranostic agent
has obvious clinical advantages over stand-
alone diagnostic or therapeutic entities; for
example, a theranostic agent exploits spe-
cific biological pathways in the living sys-
tem to detect and identify tumors and
combine this with localized specific therapeutic action. Such
agent could provide therapeutic delivery of light for elimina-
tion of heterogeneous tumor cells, by reducing the frequency
of dosage and prolonging the therapeutic action of nanosystems
in a safe, efficient, cost-effective, and targeted manner.[5–7] This
specific information allows decisions to be made on the tim-
ing, quantity, type, and choice of treatment, as well as helping
to assess and monitor a patient’s response to treatment. The
term “theranostics” was originally coined by John Funkhouser
in 2002.[8,9] Theranostics representing the most important tools
in diagnosis and treatment are becoming a rapidly growing and
well-established research field at the interface between nanotech-
nology and biomedical sciences. However, the first report of the
use of theranostic platforms using radioactive iodine as the ther-
anostic agent for imaging and treatment of thyroid cancer was
published by Seidlin et al. in 1946,[10,11] and since then radioio-
dine therapy has become the gold standard in thyroid diseases.
The last decade has witnessed especially significant advances
in the development of NPs for cancer diagnosis and treatment,
with smart nanostructured materials having the potential to
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alter their structural, morphological, and functional features
in response to specific internal (enhanced permeability and
retention (EPR) effect, protein corona formation, passive target-
ing, exchange of ion channels) and external stimuli (electric or
magnetic fields, electromagnetic radiation etc.).[12] Initially, the
use of these NPs was investigated for diagnosis and therapeutics
separately. Despite their rapidly growing success in diagnosis
and treatment, the safety and toxicity associated with such
nanosystems have emerged as a serious concern and a potential
barrier to the clinical translation of these nanoformulations.[13]
To address these safety challenges and to improve the tar-
geted therapeutic efficacy, stable biocompatible nanosystems
have also been explored.[14] All these NPs and bioconjugated
(functionalized) counterparts differ in their pharmacokinetic
and toxicity profiles owing to their size-dependent photolu-
minescent/plasmonic properties, shape, surface area, surface
charge, aspect ratio, solubility, stability, structure and surface
modification, and biodistribution in different organs.
In the last decade, there has been a significant advancement in
developing NPs as two-in-one nanotheranostic agents.[15] These
may be classified in two types: the use and loading of extrinsi-
cally “switchable” optical agents onto the surface of NPs, known
as “extrinsic nanotheranostic agents”; and the NPs with inherent
features for both diagnosis and treatment, known as “intrinsic
nanotheranostic agents.”[16] Conventionally used NPs are extrin-
sic in nature, they include polymers, liposomes, and inorganic
NPs and have limited penetration into tissues and low thera-
peutic efficacy.[17] Conversely, intrinsic NPs, such as fluorescent
quantum dots and plasmonic NPs are multifunctional, stable,
simple, and straightforward. Noble metal NPs, such as gold NPs
(AuNPs), have extensively been investigated as nanotheranostic
agents, owing to their unique characteristics, versatility and tun-
able NIR surface plasmon resonance, excellent stability, low tox-
icity, high biocompatibility, and ease of surface conjugation.[17]
Detection and treatment ofmalignancies require a clear under-
standing of the disease and associated point of clinical need. Can-
cer progression and aggressiveness are typically classified into
stages, where stage 0 means there is no cancer but only abnor-
mal cells, stage I means the cancer tumor is small and only in
one area, stage II and III mean the cancer tumor is larger and has
grown into nearby tissues or lymph nodes, and stage IV means
the cancer has spread to other parts of the body. For comprehen-
sive classification, a system referred to as TNM (Tumor, Node,
Metastasis) is used, where T refers to the size of the cancer and
its spread into nearby tissue— it can be 1 (small), 2, 3, or 4 (large);
N refers to whether the cancer has spread to the lymph nodes— it
can be between 0 (no lymph nodes containing cancer cells) and 3
(lots of lymph nodes containing cancer cells);M refers to whether
the cancer has spread to another part of the body—it can either
be 0 (the cancer has not spread) or 1 (the cancer has spread).[18]
Therefore, typical detection procedures vary greatly depending
on the type of cancer and may involve: physical examination of
any tumor-like abnormalities, laboratory tests for blood to detect
unusual white blood cell count etc. Often these tests are insuffi-
ciently specific, thus leading to invasive collection of tissue sam-
ples (biopsies), which are then tested by histopathologists em-
ploying haemotoxylin and eosin (H&E) stain andmicroscopic im-
ages. They utilize the cellular features and tissue architecture to
identify the presence of cancer and then provide a grade or stage
of cancer. Cancer and precancer grading is subjective and prone
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to human error, in addition to the fact that such tests can require
several days for the reporting process.[19–21]
There is a huge drive toward quantitative noninvasive
instrument-driven cancer detection imaging modalities; how-
ever, they are all still reliant on gold standard histopathology
to provide the definitive diagnosis and grade of disease. Imag-
ing tests like those based on computed tomography (CT), radio-
scintigraphy, magnetic resonance imaging (MRI), positron emis-
sion tomography, andX-rays have gained importance in detection
and staging of disease. All of these approaches have good depth
of penetration for whole body imaging and a reasonable spatial
resolution of the order of mm, however—with the exception of
MRI—they all result in a potentially unnecessary radiation dose
for the patient. On the other hand, optical imaging modalities,
such as fluorescence, NIR, photoacoustic, optical coherence to-
mography (OCT) and Raman spectroscopy are nondestructive,
use nonionizing radiation and therefore have no potential for in-
ducing malignancies, can have high chemical specificity, but of-
ten a low penetration depth into tissue (mm to cm). This is be-
cause tissues are highly scattering as well as absorbing (at certain
optical wavelengths) owing to components, such as water, lipids,
melanin, and hemoglobin. The light absorption is considerably
lower in the 650–950 nm spectral region, often referred to as the
“optical window” or “tissue transparency window,” and this has
paved the way to development of optical imaging modalities for
cancer detection in this spectral range.
Surgery, radiotherapy, and chemotherapy are the current gold
standard modalities to treat cancer, while photodynamic ther-
apy (PDT), photothermal therapy (PTT), magnetic hyperther-
mia, immunotherapy, stem cell therapy, and combinations of
these modalities are becoming accepted treatment methods for
specific conditions and used as adjuncts to the gold standard
methods.[22–24] Although surgery is a very efficient and safe alter-
native, it has been unsuccessful in many cases,[25] usually when
a disease has advanced to a stage where the tumor has begun to
grow outside of its primary site. On the other hand, chemother-
apy is nonselective and nontargeted, meaning that the surround-
ing healthy tissue is also regularly damaged.[26] The benefit of
PTT compared to PDT and radiotherapy is that cell death is not
dependent on the presence of oxygen, whichmay be depleted dur-
ing treatment or may already be at low levels in hypoxic tumors.
Currently employed techniques for in vivo diagnosis are lim-
ited by a lack of specificity, and treatments are usually associated
with systemic toxicity. Light-triggered modalities could provide
an appropriate nanotheranostic platform for multimodality tu-
mor imaging in guiding the therapeutic process, such as PTT,
which has recently gained increasing attention as an effective and
safe approach.[26] PTT offers a relatively noninvasive and gentle
alternative for cancer treatment, using targeted AuNPs of spe-
cific shapes that absorb NIR light and produce localized heat for
tumor ablation. These photoabsorbers (AuNPs) can be injected
systemically or locally into the tumor to selectively increase the
temperature under laser irradiation. Tumor destruction is thus
achieved by raising the temperature to a sufficient level over a
required period. In this therapeutic strategy, the photon energy
is converted into heat and, once the temperature exceeds ≈42 °C
for a sufficiently long time, this will induce localized cell death.
A commonly accepted “rule of thumb” when considering heat-
ing for hyperthermia relates to the thermal dose unit. This is de-
fined based on the cumulative equivalent minutes of exposure at
43 °C causing approximately half of cell to die, when cells are ex-
posed to this temperature for 60 min.[27,28] Thermal dose units
have been derived from the observation, in many cell types, that
above 43 °C a similar level of cell damage is achieved in approxi-
mately half the time when the temperature is increased by 1 °C.
PTT does not have the same potential for severe infection that
can be encountered after surgery. It also overcomes the side ef-
fects of chemotherapy by circumventing the use of systemically
toxic drugs.[29] Furthermore, unlike in radiotherapy and PDT, the
presence of oxygen is unnecessary in PTT to induce cell death.
Currently, many photothermal agents, such as noble metal
nanostructures, transition metal chalcogenides and oxides,
carbon-based materials, and organic compounds have been
widely investigated.[30] Furthermore, AuNPs have great pho-
tothermal theranostic effects, strong localized surface plasmon
resonance and photostability in contrast to other agents.[31] Gold
nanostructures have received a great deal of attention as ther-
anostic agents due to spatiotemporal selectivity and specificity
for disease destruction when functionalized with targeting moi-
eties, ease of surface functionalization/modification, low toxicity,
high biocompatibility, high surface-to-volume ratio, optical prop-
erties, and interplay of size- and shape-dependent NIR imaging
and therapeutic efficacies.
AuNPs have been produced in different shapes, such as
nanoshells,[16] nanorods (NRs)[32] nanocages,[33] nanostars,[17]
nanospheres,[32] and core–shell structures.[34] Localized surface
plasmon resonance (LSPR) wavelengths of AuNPs can be tuned
from the visible to the NIR region by changing the size and shape
of NPs. AuNPs can be functionalized to make them selective and
targeted toward diseased tissues, and have been explored as mul-
tiplexed contrast agents for several diagnostic techniques (such
as computed tomography,[8] surface enhanced Raman scattering
(SERS),[7] and photoacoustics[6]) coupled with PTT for the diag-
nosis and treatment of cancer.[22–26] Each of these diagnostic tech-
niques has its own merits and limitations in visualizing a tumor
for targeted PTT based on their specificity, sensitivity, potential
to detect and provide image-guided therapeutic processes, and in
situ excitation of theranostic agents.[35]
Apart from AuNPs, there are various different classes of
photothermal theranostic agents including transition metal
chalcogenides and oxides (e.g., CuxSy, Cu2–xSe, MoS2, WS2,
FeSe2, FeS, TiS2, MoOx, WxOy, Ti8O15 with different structures,
e.g., nanosheets, nanodots, and spherical NPs), carbon-based
materials (such as single-walled carbon nanotubes, pristine
graphene, graphene oxide, reduced graphene oxide, functional-
ized graphene quantum dots, graphene nanoribbons), organic
materials as well as organic dye loaded micelles, liposomes, and
protein-based nanocomposites (polymers of polyaniline (PANI),
polypyrrole (PPy), and poly(3,4-ethylenedioxythiophene):poly(4-
styrenesulfonate) (PEDOT:PSS)).[36,37] A review of the develop-
ment of these photothermal theranostic agents is beyond the
scope of this discussion but has been reported elsewhere.[38] The
diagnostic ability and photothermal heating efficiency of transi-
tion metal chalcogenides and oxides are reduced when their size
is decreased, which limit their further biomedical application.[39]
In the case of carbon-based materials, the poor dispersibility and
stability in biological solutions have been shown to induce side
effects and enhanced toxicity profile, which may restrict their
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further application.[40] However, this challenge can potentially
be addressed by modifying the surface of graphene with
polyethylene glycol (PEG), polyacrylic acid, and other hydrophilic
groups.[41] Organic materials and dyes have been shown as
promising photothermal theranostic agents, due to the high ab-
sorption cross-section and fluorescent emission that can be uti-
lized for tumor detection and high NIR photothermal effects.
However, long-term toxicity and photobleaching and unclear
biodegradation mechanisms limit their further application in
nanotheranostics.
Due to the tunable and controllable LSPR of AuNPs, provid-
ing a number of functions, such as photothermal conversion
and SERS activity, they make an ideal plasmonic material for
use in the development of nanotheranostics for personalized
medicine. The LSPR can be modified adjusting the aspect ra-
tio, size, shape, and aggregation. These unique plasmonic char-
acteristics of AuNPs can be employed in PTT by the transfer of
electrons from the conduction band of NPs and their fast deac-
tivation through e–e scattering, to produce high-potential-energy
“hot” electrons which in turn induce localized heat in tissues to
initiate tissue ablation.[42,43] Recently, efforts to raise SERS sig-
nals and the conversion of photon energy to thermal energy have
mainly focused on size, shape, surface chemistry, and LSPR tun-
ability of AuNPs.[44] Gold nanostructures have recently been ex-
ploited as multifunctional nanotheranostic systems for simulta-
neously obtaining cell-targeted SERS imaging and PTT. In vitro
and in vivo findings suggest that smart and versatile gold nanos-
tructures are promising NIR light-triggered and targeted thera-
nostic platforms for imaging-guided PTT of cancer, which may
provide a solution to the bottleneck problems of both diagnosis
and treatment, including limited penetration depth and oxygen-
deficient microenvironments.[45–50]
In this review, we will survey recent advances in plasmon-
assisted gold nanostructures. Section 2 will give the readers the
basics of nanoplasmonics, synthesis, morphology, and unique
features of gold nanostructures. We will successively describe
the optical and thermal properties of AuNPs. In Section 3, we
will highlight the potential dark- and phototoxicity, biological fate,
biodistribution, and cellular uptake of these nanostructures to
target tumors while remaining nontoxic to normal cells. Sec-
tions 2.5 and 2.6 will provide a snapshot on the application
of AuNPs in a wide spectrum of diagnosis (fluorescent, mag-
netic resonance, photoacoustic imaging, Raman spectroscopy)
and treatment (PTT), with a special focus on thermal biology
of AuNPs. In Sections 4, we will review the in vitro and in vivo
studies in which photothermal theranostic approaches have been
reported. Finally, Section 5 will highlight the barriers and chal-
lenges in translating the AuNPs into clinical settings, with a focus
on future perspectives for triggering chemical transformation of
AuNPs to enhance the efficiency of light-triggered nanotheranos-
tic modalities.
2. Designing Smart Gold Nanostructures
Cancer theranostics has been a key research area in the past
decade and is growing in importance, as researchers around the
world are now able to more effectively bridge diagnostic and ther-
apeutic strategies. Though the term “theranostics” has already
Figure 1. Schematic diagram showing the important functionalities of
gold nanostructures.
been in use for some time now, it has proved to be challenging to
develop a single platform providing the best of both worlds. This
has given rise to multiple components combined into one nanos-
tructure in complicated strategies, unleashing various combina-
tions of diagnostic and therapeutic approaches, hence diversify-
ing as well as defocussing the outcome. To this end, gold nanos-
tructures have been one of the key single-mode platforms, re-
alizing the concept of theranostics with diagnostics supported
by its optical properties, therapy provided by the photothermal
properties and its inherent biocompatibility (compared to quan-
tum dots, iron oxide NPs etc.) for use in vivo. This concept has
schematically been depicted in Figure 1. Many research groups
worldwide are working on the design of gold nanostructures for
smart theranostics. As these need to be employed in vivo, sec-
ondary functionalities are needed in order to provide active tar-
geting to specific sites and/or passive targeting due to the EPR
effect, higher blood circulation times due to good biocompat-
ibility, etc. Primarily, after administration (oral, through injec-
tion at the site or intravenous), the nanostructures are tracked
or imaged by a diagnostic modality (namely, noninvasive optical
spectroscopies) to detect the specific subcategory of disease de-
pending on the employed functionalization (molecular targeting
groups on the nanostructures). A potential way to detect and iden-
tify heterogeneous diseases simultaneously, as well as the stage
of the disease, would be to employ multiplexed (multiple target-
ing group-diagnostic label pairs) gold nanostructures. Following
this, should a specifically defined signal be obtained, the therapy
would be triggered specifically at the disease site. The diagnostic
modality should thereafter also allow monitoring of the effective-
ness of the therapy. Achieving this goal would help in providing
personalized treatments to patients.
2.1. Why Gold Serves as an Efficient Photothermal Agent?
PTT is referred to as a process which involves the selective heat-
ing of the local environment in which the PTT agent is employed.
In particular, common PTT agents absorb light hence promoting
electronic transitions from ground to excited states, followed by a
nonradiative decay leading to heating of the local environment of
the PTT agents. PTT agents, such as natural chromophores and
light-absorbing dyes have relatively low absorption cross-section,
poor light-to-heat conversion, and photobleaching, thereby mak-
ing them inefficient as potential clinical theranostic agents. In
contrast, plasmonic nanostructures benefit from high light-to-
heat conversion and eliminate the possibility of photobleaching.
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Figure 2. Photothermal properties of NPs based on A) material (other parameters identical) and B) size. Adapted with permission.[55] Copyright 2007,
Elsevier.
These structures have readily induced surface plasmons (oscil-
lations of the conduction band electrons at the nanoparticle sur-
face) that can be resonant with the incident light thus producing
an LSPR. Heat is produced by resistive heating from the oscillat-
ing electrons within the surface of themetal, when light energy is
absorbed by the NP, which typically depends on the LSPR profile
of the NP.
It is important to consider the temperature rise required for
triggering cell death and hence for application in cancer therapy.
It has been suggested that cell death can be induced by increas-
ing the body temperature to a hyperthermic temperature of 42–
47 °C.[51,52] It is worth noting that the induced temperature rise,
even when it is due to similar nanostructures, may vary depend-
ing on their difference in heat absorbing and dissipating environ-
ments (aqueous environment, in vitro or in vivo), heat transduc-
tion and local thermal conduction properties, thereby making it
difficult to compare directly their efficiencies in different envi-
ronments.
Hence, in order to utilize gold nanostructures effectively in
PTT, it is vital to be able to specifically tailor them for use.
PTT would require gold nanostructures to primarily provide an
efficient light-to-heat conversion by first maximizing the light
absorbed by the nanostructures while avoiding significant loss
of energy due to phenomena, such as scattering, fluorescence,
phosphorescence, etc.[23,32,36] In this perspective, it is vital tomax-
imize the light absorption of the metal nanostructures at and
around the wavelength that can be medically used to trigger ther-
apy in patients, which in turn depends on the tissue transparency
window 650–950 nm, i.e., a region of highest penetration through
the tissue.[53,54] Hence, gold nanostructures have been prepared
in such a way that the LSPR overlaps with the tissue transparency
window. Another important consideration is the laser excitation
line to be used for this purpose. Most studies report the use of
808 nm excitation line and hence gold nanostructures with LSPR
peak positions in vicinity of the laser line would provide an en-
hancement in the performance of the nanostructures (detailed
discussion and examples in Section 2.3). It should be noted that
the optical extinction of gold nanostructures stems from scatter-
ing and absorption, where absorption dominates in most cases.
Detailed understanding of the relationship between these param-
eters can be found in the reports by Jain[53] and Hu.[54]
Govorov and Richardson[55] have discussed in great detail the
correlation between nanostructure design (for simplicity, its ra-
dius) and temperature increase (ΔT). The equation below pro-
vides the temperature increase as a function of distance, r, from
the center of a single NP
ΔT (r) =
VNPQ
4𝜋k0r
(1)
where VNP is the NP volume, and Q or Q(rnp,t) is a function of
the NP radius, rnp, and time, t, and k0 is the thermal conduc-
tivity of the surrounding medium. This expression is valid out-
side the NP, i.e., for r > rnp, and is the calculated heat genera-
tion (assuming that the incident light wavelength is much longer
than the NP radius). The maximum temperature rise occurs at
r = rnp and hence the maximum temperature can simply[55] be
given as ∆Tmax 𝛼 rnp
2. Figure 2A features the total heat genera-
tion (qtot = VNPQ) for both plasmonic and semiconductor NPs.
Typical semiconductors (e.g., CdSe and CdTe) exhibit low heat
generation rates compared to those of plasmonic NPs, justifying
the use of plasmonic NPs as PTT agents. For plasmonic NPs, the
heat generation ratemimics their plasmon behavior.[55] Addition-
ally, silver presents a tenfold increased heat generation compared
to gold at their respective plasmon peaks and for identical pa-
rameters, i.e., rnp = 30 nm, light flux I0 of 5 × 104 W cm−2 and
surrounding medium, as shown in Figure 2A.[55] This heat gen-
eration slowly tails off in the NIR window where gold shows a
slightly better performance than silver, giving gold an edge es-
pecially for in vivo theranostic applications. Furthermore, the in-
stability of silver (especially in biological media) also discourages
its use, establishing gold as a superior choice as PTT agent. Fig-
ure 2B shows a temperature rise with increasing a) light flux and
b) NP size, when the wavelength of light is tuned to match the
LSPR peak maximum. This is also supported by the experimen-
tal reports byQin et al.[56] which showup to two orders of increase
in absorption cross-section,Cabs, with increasing NP size from 15
to 100 nm, thereby confirming the significance of size in heating
efficiency.
2.2. Synthesis of Gold Nanostructures for Theranostics
Although both top-down and bottom-up approaches have widely
been used for nanostructure design, the bottom-up approach of
forming gold nanostructures from gold atoms (gold salt reduc-
tion methods) has been popular for preparing colloidally-stable
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Table 1. Nanostructures and their tunable properties.
Nanostructures and their TEM images Size LSPR ranges Synthesis
routes
Tunability
a: absorption coefficient; s: scattering 
coefficient
Refs
Nanospheres
1.5–180 nm 520–650 nm
Turkevich, Brust, seed-
mediated growth, 
laser-assisted 
D(nm) λLSPR
λLSPR
λLSPR
a/ s
20 521 100
40 528 17
80 549 1.5
[53,57,65–67]
Adapted with
permission.[65]
Copyright 2014,
Wiley.
Nanorods
20–1000 nm 600–1800 nm Seed-mediated growth, 
electrochemical
reduction, microwave-
assisted, solvothermal
reduction
D(nm) a/ s
17.5 (A=3.9) 788 34
22.86 (A=3.9) 797 12.5
43.7 (A=3.9) 842 1.85
22.86 (A=3.1) 727 14.3
22.86 (A=4.6) 863 10
 A: aspect ratio
[53,58,61,68,69]
Adapted with
permission.[69]
Copyright 2012,
ACS.
2D nano plates, nanosheets, nano 
triangles
40–1000 nm
(edge)
5–50 nm
(thickness)
700–1300 nm Electrochemical
reduction, microwave
assisted, ultrasound
assisted, photo-induced
Tunability is obtained by 
altering the dimensions and 
importantly by the shape.
[62,63,64]
Adapted with
permission.[63,64]
Copyright 2014,
ACS.
Copyright 2014,
ACS.
Nanoshells 10–400 nm 520–900 nm Template 
directed 
synthesis
Inner D (nm) a/ s
40 (d=30) 843 11.11
60 (d=10) 892 1.56
50 (d=20) 704 0.46
120 (d=20) 1120 0.40
 d:shell thickness
[53,70–74]
Adapted with
permission.[70]
Copyright 2013,
ACS.
Branched NPs, nanostars, 
tetrapods, hexapods etc.
45–300 nm 550–800 nm
Seed-mediated
growth
Tunability is achieved by 
altering the size, branch density, 
branch length and its tip 
sharpness. Though multiple 
parameters can be manipulated, 
batch-to-batch reproducibility 
can be an issue. 
[75–77]
Adapted with
permission.[75-77]
Copyright 2004,
2010 and 2012,
ACS.
Nanocubes, nano frames etc. 20–200 nm 400–1200 nm Seed-mediated 
growth, galvanic 
replacement reactions
Tunability is obtained by 
altering the size and chemical 
composition like Ag/Au bi or 
multi-layer nanostructures, as 
well as solid to porous to hollow 
structures.
[62,78,79]
Adapted with
permission.[78]
Copyright 2013,
ACS.
structures required for in vivo applications. There have been nu-
merous reports and reviews[57–62] focusing on gold nanostructure
synthesis to which the reader is directed. Table 1 lists the variety
of gold nanostructures that have been reported in the literature
and most importantly reflects on their tunability of shape, size,
etc., to manipulate the optical properties, especially LSPR and
photothermal properties (ratio of absorption to scattering coef-
ficient 𝜇a/𝜇s).
Nanorods, nanoshells, branched nanostructures, and
nanoassemblies have gained popularity in this field and de-
mand a more detailed overview. In contrast to spherical NPs,
NRs inherently feature a longitudinal LSPR in the NIR region
and can be tuned by manipulating their size and aspect ratio
(AR), as shown in Figure 3. Recently, Takahata et al. have re-
ported ultrathin NRs with an AR of about 10–20 that exhibit
LSPR in the mid-IR (MIR) region (see Figure 3B).[80] Although
their LSPR overlaps with the transparency window which should
translate into higher photothermal efficiency, the typical polydis-
persity of the NRs (in a synthesized batch) is higher than that of
the spherical NPs, effectively lowering their average absorption
Adv. Sci. 2020, 1903441 1903441 (6 of 28) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
Figure 3. A) Nanorod aspect ratio-dependent LSPR peak in the near-IR region. Adapted with permission.[82] Copyright 2014, American Chemical Society.
B) LSPR in mid-IR with ultrathin NRs. Adapted with permission.[80] Copyright 2018, American Chemical Society.
Figure 4. Manipulating nanoshell properties. A) Evolution of nanoshell growth on a silica nanoparticle (TEM and UV–vis). Adapted with permission.[70]
Copyright 2013, ACS. B) Theoretically calculated optical resonances of metal nanoshells silica core, gold shell over a range of core radius:shell thickness
ratios. Adapted with permission.[73] Copyright 1998, Elsevier.
cross-section.[56] Another criterion for consideration is that
heating causes melting and reshaping of the NRs, yielding NRs
with lower AR and LSPR than the original, potentially making
them impractical for therapeutic use as they would change
their light-heat transduction efficiency during a treatment cycle.
Murphy and co-workers[68,81,82] have elaborately investigated and
reported this effect.
Other nanostructures that have become popular are gold
nanoshells and gold nanostars as their LSPR peak can be posi-
tioned in the NIR region. Manipulating the shell thickness in
the range of 1–30 nm for gold nanoshells and the number of
branch, tip sharpness, length of the tip for gold nanostars pro-
vides a handle over its 𝜆LSPR tunability. Nanoshells
[70,73] were syn-
thesized initially onto dielectric silica cores, and the stagewise
growth of the shell involved formation of the gold seeds which
later coalesced into the silica sphere (having nanoroughness) fi-
nally giving rise to a continuous gold shell over the silica core
(as depicted in Figure 4 and Table 1). With an increase in shell
thickness, the LSPR is blueshifted. Thus, a shell thickness of 2–
10 nm was ideal to provide a NIR LSPR peak, as depicted in Fig-
ure 4B.[73] However, upon completion of the shell formation, a
secondary peak at a lower wavelength is observed, in addition to
the primary LSPR peak, with reduced extinction as compared to
its previous partial shell stages.[70] Recently, various nanomateri-
als, such as Pt/Pd[72] or magnetic NPs[83] have been utilized as
cores to provide added functionality to the hybrid nanostructure
system.
Interesting nanostructures, such as branched gold NPs and
nanostars have also gained popularity. Marzán and co-workers
have strategically employed poly(vinylpyrrolidone) (PVP) and
dimethylformamide (DMF) to obtain gold nanostars[84,85] with
tunable dimensions and optical properties. By varying reac-
tant ratios and synthesis temperatures, they have reported a
wide range of minimally branched morphologies to highly
spiked nanostar morphologies. Figure 5 illustrates the ability to
manipulate the LSPR peak position by controlling the different
aspects of the nanostar morphology, which can be obtained by
varying and optimizing the synthesis temperatures, reactants,
reactant ratios, etc. Studies suggest NIR LSPR peaks were ob-
tained for nanostars of 100–200 nm and more with high poly-
dispersity. Though such nanostructures have shown promising
results, such size ranges hinder their applications in vivo due to
their low blood circulation times resulting lower effectiveness in
theranostic applications. Although there are controversies on the
exact size values, Blanco and co-workers[12b] suggest that spheri-
cal gold NPs>150 nm in diameter, nanoplates, and NRs and pos-
itively charged NPs have a higher tendency to accumulate in the
lungs, liver, and spleen, whereas, spherical 5 nmNPs accumulate
more readily in the kidneys, i.e., have higher chances of being ex-
creted from the body. This is discussed further in Section 3.
Additionally, arranging NPs into nanoassemblies[86–92] also
suffices to redshift the 𝜆LSPR into the near-NIR 600–800 nm
region. As the nanoassemblies should also satisfy the require-
ment of being sub-100 nm in size, hence dimers of 40 nm, NP
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Figure 5. LSPR dependency on nanostar morphology. A) Star tip-dependent LSPR. Adapted with permission.[83] Copyright 2011, Wiley. B) Synthesis
conditions manipulated for change in tip sharpness and thereby LSPR. Adapted with permission.[85,86] Copyright 2010, American Chemical Society; and
Copyright 2012, IOP.
assemblies of smaller sizes (about 15 nm diameter) and combi-
nations thereof have become relevant. These customized assem-
blies contain multiple nanojunction “hot-spots” featuring high
electric fields and redshifted LSPR. Some of such morphologies
have been shown in Figure 6 which exhibit LSPR of about 615–
750 nm.
Core-satellite morphologies allow controlling the satellite den-
sity and hence hot-spot density, along with the use of any shaped
core (spherical, NRs, nanostars, etc.) or satellite (spherical or
NRs).[91,93,94] Nanobranched morphologies have gained popu-
larity due to their relatively broad NIR absorbance.[88] Such
nanoassemblies offer the added advantage of boosting the tem-
perature increment of the surroundings over and above that of
the individual NPs.[95] It is worth mentioning that, with more
complicated nanostructure shapes and designs, both polydisper-
sity (e.g., as reported for branched nanoantennas[96]) and synthe-
sis scale-up becomes an issue.
2.3. Manipulating Photothermal Efficiency of Gold
Nanostructures
This section discusses the effect of the nanostructure design in
maximizing the photothermal temperature increase with some
relevant examples. Particularly, we discuss certain nanostruc-
tures that have gained prominence for use in PTT like NRs and
nanostars alongwith their structure-photothermal relation. Chen
and co-workers[97] report interesting correlations between gold
nanorod structures, their optical and photothermal efficacy by
undertaking a series of experiments, where temperatures have
been recorded from NP colloids with a thermocouple after ex-
posure to laser. They demonstrate LSPR dependency of the pho-
tothermal properties of gold nanostructures with 809 nm laser
excitation. Figure 7A shows that among a variety of gold NRs
with LSPR ranging 600–950 nm (a and b), the highest temper-
atures were achieved for gold NRs with an LSPR coinciding with
the laser line (marked with dotted line in Figure 7Ac)). They also
suggest that coating gold nanostructures with strongly light ab-
sorbing materials like (Ag2S, ZnS, etc.) result in LSPR shift to
NIR region and help in improving the photothermal conversion
efficiencies. It is important to point out that though Ag2S, ZnS,
etc., aid in light absorption, it negatively impacts the potential for
diagnostic applications using surface enhanced Raman signals
and therefore may not be an ideal solution.
Furthermore, NP volume, assembly nanostructures, shell coat-
ing have also been reported as factors influencing photothermal
properties. Among others, nanostar morphologies have been in-
vestigated in great detail. Chatterjee and co-workers[98] studied
nanostars and emphasize the importance of tip sharpness in es-
calating the surrounding temperature (as depicted in Figure 7B)),
thereby promoting higher cell death. Laser heating of the nanos-
tructures incubated at the tumor site was carried out with a con-
tinuous wave infrared diode laser (5.0 mW) at 785 ± 5 nm for
20 min. Temperature rises of ≈30 °C has been reported at the
sharpest tips within 20 min time. In contrast, lowering of tip
sharpness resulted in redshifted LSPR peak, beyond 785 nm,
which dramatically hampered its photothermal performance, i.e.,
the temperature increase of less than a few degrees observed.
Importantly, a study by Wang and co-workers[99] explicitly com-
pares different morphologies of gold nanostructure and their
PTT temperature increase behavior. Figure 7C) features gold
nanohexapods, NRs, and nanocages with almost identical LSPR
peak position (coinciding with the laser line of 805 nm, pink dot-
ted line in figure) and demonstrates that although all the nanos-
tructures aid in temperature rise, the nanohexapods perform bet-
ter when used in a mouse tissue model. Particularly, the NRs
are reported to reach 4 °C higher than the nanocages, while the
nanohexapods attain 2–3 °C higher than the NRs, at 5 min of ex-
posure each.
Researchers have also been interested in nanoassemblies as
alternative nanostructures.[45,48] An interesting study by Tian
and co-workers[100] compare the core-satellite nanoassemblies
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Figure 6. Designing and controlling gold nanoassemblies. Adapted with permission.[87,91,92] Copyright 2013 and 2014, ACS; and Copyright 2014, RSC.
with spherical gold cores (AuNPS), as well as gold nanorod
cores (AuNPR), as shown in Figure 7D(a). The off-resonant
nanoassembly structures (LSPR peak position does not coincide
with the laser excitation of 808 nm) provided temperature in-
crease of AuNPR solution (ΔT= 24 °C) compared to AuNPS solu-
tion (ΔT= 8 °C) andwater (ΔT=< 1 °C). This can be attributed to
the around three times higher absorbance at 808 nm for AuNPR
than AuNPS (UV–vis spectrum b and temperature plot c). Tun-
ing the absorbance of gold nanostructures to the NIR II band
(1000–1350 nm) for PTT have been attempted by creating black
body type nanostructures with significant absorption in both NIR
I and NIR II.[100] It can thus be fairly concluded that the highest
photothermal efficiency can be obtained with nanostructures fea-
turing the highest absorbance at the laser excitation wavelength.
It is important to realize that for a true comparison of efficiency,
the temperature rise is dependent on a multitude of parameters
that can affect the absolute increase in temperature.
2.4. Thermal Dosimetry
There is a commonly accepted “rule of thumb” when considering
heating for hyperthermia which relates to the thermal dose unit.
This is based on the cumulative equivalent minutes of exposure
at 43 °C, whereby, when cells are exposed to this temperature for
60 min, approximately half of cell will survive.[26,27] Note, this is
based entirely on the cell type and needs to be ascertained for
the cell type targeted. However, thermal dose units have been de-
rived from the observation, in many cell types, that above 43 °C
a similar level of cell damage is achieved in approximately half
the time, when the temperature is increased by 1 °C. Sapareto
and Dewey[101] suggested the use of “degree-minutes” as the dose
calculator which converts all thermal exposures to “equivalent-
minutes.” They developed a formula where the time at 43 °C,
t43 = t*R(43-T), where, t is the time in minutes at T °C and R = 0.5
for T > 43 °C and R = 0.25 for T < 43 °C.
2.5. Gold Nanostructures as Optical Diagnostic Agents
With the focus on “theranostics” and an aim in making clini-
cal care both more effective and reduce procedures for patients
to undergo, as compared to employing two separate agents for
diagnosis and therapy, gold nanostructure-based PTT needs to
complement the associated diagnostic modality. Below we will
discuss briefly the different diagnostic modalities supported by
gold nanostructures and provide some examples thereof. Gold
nanostructures being plasmonic can be employed for optical-
based diagnostic modalities like fluorescence, Raman, photoa-
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Figure 7. A) Example of tuning the PTT temperature by tuning LSPR peak position. a)TEM images of gold NRs with different aspect ratios, b) their
respective UV–vis spectra, c) temperature increase as a function of LSPR peak positions with 809 nm laser line (marked in dotted line). Adapted with
permission.[97] Copyright 2013, American Chemical Society. B) Example of tuning the PTT temperature by tuning the tip sharpness of gold nanostars. a)
Temperature-time plot of nanostars with increasing tip sharpness alongwith TEM image, b) Electric field intensity plot with increase in tip sharpness of the
gold nanostars. Adapted with permission.[98] Copyright 2015, American Chemical Society. C) Comparison of differentmorphological gold nanostructures
with similar LSPR peak positions. a,b) UV–vis spectra and TEM images of gold nanohexapods, NRs, and nanocages, c) thermographs of tumor-bearing
mice receiving photothermal treatment for different periods of time. The mice were intravenously administrated with aqueous suspensions of PEGylated
nanohexapods, NRs, nanocages, or saline. Adapted with permission.[99] Copyright 2018, American Chemical Society. D) Example of core-satellite gold
nanoassemblies with off-resonant LSPR peak positions. a) Schematic representation of the formation of such nanoassemblies with a nanosphere as the
core (AuNPS) and nanorod as the core (AuNPR) along with the TEM images of the prepared nanoassembly structures, b,c) their respective UV–vis and
temperature-time plots of the respective nanoassembly structures. Adapted with permission.[100] Copyright 2010, Wiley.
coustic imaging, etc., in addition to more commonplace tech-
niques such as X-ray CT.
2.5.1. X-Ray CT Imaging
X-ray CT imaging is an important form of noninvasive 3D imag-
ing due to its almost universal availability in medical clinics and
hospitals, making infrastructure implementation and acceptabil-
ity easy. Contrast in X-ray imaging is derived from the differ-
ence in mass attenuation between two tissues. Materials with a
high atomic number or density, such as bone absorb more X-
rays, making them detectable. Contrast agents play an impor-
tant role in allowing higher energy, safer scans with high con-
trast by introducing high atomic number media like iodine or
gold colloid into the body. The attenuation is often measured in
Hounsfield units (HU) which is normalized to the attenuation
of water (= 0 HU) and scales linearly.[102] The HU values be-
tween different research groups are not directly comparable as
it heavily depends on the energy of the X-ray scan. Iodinated con-
trast medium (concentrations of 150–400 mg mL−1 iodine) has
been employed as the primary X-ray contrast agent till date. Re-
search has provided good knowledge in the various aspects where
gold nanostructures[102,103] could be utilized. Maltzahn and co-
workers[104] report the benefits of PEG—protected gold NRs as
X-ray contrast agents. GoldNRswith superior spectral bandwidth
and optical conversion efficiency for photothermal heat genera-
tion provides an improved circulation half-life in vivo (t1/2 ≈17 h,
compared with gold nanoparticles (NPs) and gold nanoshells)
and importantly ≈ two fold higher X-ray absorption than clin-
ical iodine contrast agent. On the other hand, Ma et al.[105] re-
port shape-independent X-ray absorption for gold nanospheres,
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Figure 8. Examples of gold nanostructure employed in optical diagnosis in mice tumor models by injecting the customized gold nanostructures, along
with featuring their specific property for specific diagnosis. A) X-ray CT imaging demonstrating tumor detection (marked with arrow) for pre- and
postinjection. Adapted with permission.[106] Copyright 2016, Elsevier. B) Ultrasound imaging demonstrating tumor detection (marked with arrow) in
injected and noninjected leg of mice. Adapted with permission.[106] C) NIR fluorescence imaging with coated gold NRs after 1 and 24 h demonstrating
tumor detection (marked with arrow). Adapted with permission.[107] Copyright 2011, American Chemical Society. D) Raman (SERS-based) spectroscopy
employing gold NRs demonstrating tumor detection by comparing the spectrum of skin, tumor, and control tumor. Adapted with permission.[108]
Copyright 2010, Wiley.
nanospikes, and NRs per mass of Au cellular uptake, but points
out that the cellular uptake and hence the X-ray efficiency trend
followed nanospheres > nanospikes > NRs. Typically, gold con-
centrations of 100 mg Au mL−1 has been studied. Figure 8A
demonstrates the X-ray contrast obtained with gold nanostruc-
tures and quantifies them in HU units.
2.5.2. Photoacoustic (PA) and Associated Ultrasound Imaging
PA imaging uses pulsed light to transiently heat a local ab-
sorber, which could be red blood cells or exogenous (NPs) caus-
ing heating of the local surrounding, which upon thermal ex-
pansion of the tissue causes a pressure wave that is detected
through ultrasound. Laser sources typically used in photoacous-
tic imaging comprise of Q-switched, pulsed Nd:YAG lasers pro-
viding several tens or hundreds of mJ at 1064, 532, or 355 nm,
pumping broadband optical parametric oscillators to give tun-
able nanosecond pulses across the visible and near infrared spec-
tral region. Ultrasound imaging, on the other hand, is based
around the creation of acoustic waves in the tissues and measur-
ing how they are reflected and attenuated by the tissues and their
interfaces.
Employing light in the NIR window for PA is advantageous
and as such gold nanostructures featuring NIR absorbance
are ideal candidates. Therefore, gold nanostructures designed
by varying size or morphology (e.g., nanospheres, nanoshells,
nanocages, and NRs) have been utilized by this imaging tech-
nique in the research phase.[109] As tumors are often quite small,
PA and ultrasound techniques do not always provide sufficient
spatial resolution or specificity required for a full diagnosis.
However they are often able to identify abnormalities for fur-
ther investigation and are relatively cheap, as compared to whole
body scanners, such as MRI and X-ray CT and hence have an
advantage. Typically, the NP coating plays an important effect
on imaging efficiency, for example, in perfluorooctyl bromide
(PFOB) coated gold nanoshells,[110] PFOB with higher acoustic
impedance than air, thus boosting ultrasound imaging. An exam-
ple is shown in Figure 8B. On the other hand, gold nanobranched
structures, gold nanostars, gold NRs have also been exploited
for PA imaging.[111] Targeted gold (NPs) in the concentration of
108–109 NPs mL−1 exhibited significant PA signals when com-
pared with nontargeted AuNPs and the ADS740WS NIR dye
in cell/gelatin samples at 680 nm wavelength illumination.[112]
Recently, a switchable PA imaging agent has been reported by
Kim et al.[113] with gold NRs and the presence or absence of the
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silver coating onto the gold NRs provided a PA signal off or on,
respectively. This was demonstrated in vivo by IV injection of sil-
ver etchant into the previously injected silver-coated gold NRs,
where the PA signal would switch on after reaction with the
etchant.
2.5.3. NIR Fluorescence Imaging
Fluorescence dyes andmore recently quantum dots have become
popular as fluorescent agents. First reported by Mooradian,[114]
the fluorescence of bulk gold, was observed to be very weak with
a quantum yield of the order of 10−10 and hence was limited
in its application. But lately, strong fluorescence with a quan-
tum yield of up to 10−3 has been reported for gold (NPs) and
nanoshells, paving way for their application as NIR fluorescence
agents.[115–117] Additionally, gold nanostructures feature benefits
of no photobleaching, observed with other dyes, and depend-
ing on the phenomenon exploited gold can even enhance flu-
orescence of certain organic dyes utilizing the phenomenon of
metal-enhanced fluorescence. Figure 8C depicts a study where
tailored gold nanostructures have been employed to detect tumor
(marked with arrow) where the higher NP uptake into the tumor
can be readily observed.
2.5.4. Raman Spectroscopy
Last but potentiallymost importantly, there has been tremendous
work in the field of employing gold nanostructures for SERSdiag-
nosis. Conventional (normal) Raman signals are molecular spe-
cific and able to distinguish pathological tissues and cells,[118–120]
however, they are inherently weak and therefore without the use
of fiber optics to deliver laser light and efficiently collect Raman
signals,[121,122] it is unlikely that Raman will be able to probe dis-
eases in deep solid organs, although deep Raman methods are
showing some promise.[123,124] However, the SERS phenomenon
of boosting Raman signals of a molecule (acting as a label or tag)
when positioned at a “hot-spot” (NP surface or NP–NP junction)
can be well-utilized as an optical diagnostic technique. It utilizes
the enhancement of electric field around plasmonic nanosur-
faces, which can be further amplified at a NP–NP junction (in
plasmonic nanoassemblies) and are referred to as hot-spots.[91,92]
When a molecule with high Raman cross-section (often small
aromatic molecules) sits in such a hot-spot, the inherent Raman
signals of the molecule are dramatically enhanced up to 4–8 or-
ders of magnitude in signal intensity. The noble metal plasmonic
substrate, most often Au or Ag, acts as the SERS signal amplifier.
This SERS enhancement of molecules has been either applied
in chemo/biosensing, i.e., unknown molecule brought close to
SERS amplifier for detection and/or quantification, or known
molecules labeled onto SERS amplifiers and its location tracked
for detection of tumors.[38,125] NP morphologies (shapes, sizes,
and assembly structures) dictate the plasmon coupling, LSPR,
and electric field at the hot-spot which directly influences the
SERS enhancement of the Raman signals. Designing the nanos-
tructure for SERS biomedical diagnosis in bioassays, cells, as well
as clinics, have been reviewed in detail in some of the recent
articles.[126,127]
One of the early successful studies using SERS in vivo demon-
strated use of labeled SERS gold nanostructures, as shown in
Figure 8D, where tumor detection was achieved by spectrally
differentiating the SERS signature of the skin and tumors and
cross-referencing them with the label.[108,128,129] SERS benefits
from the potential for multiplexed detection when using mul-
tiple labels, due to the sharp well-defined spectral peaks. Ou
and co-workers[130] tracked SERS of duplexed 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid HEPES-reduced gold nanostars
(50–70 nm size) and observed a maximum accumulation of gold
nanostars occurring 6 h postintravenous (IV) delivery. Monitor-
ing the 1325 and 1580 cm−1 Raman shifted peaks for the SERS tag
DTNB (targeting PD-L1) and pMBA (targeting epidermal growth
factor receptor (EGFR)), respectively, both in vivo and ex vivo du-
plexed detection was achieved.
Recent advances toward the possibility of SERS for use in hu-
mans came from the demonstration by Stone et al. of multi-
plexed deep tissue imaging and detection by a spatially offset
Raman spectroscopy (SESORS) and transmission Raman spec-
troscopy (TRS) set-up with gold core encapsulated with silica
shell nanostructures achieving a record detection depth of up
to 5 cm from tissues.[131] This was followed by a demonstration
of functionalized nanoparticle labeling of bone for SESORS[132]
and for glucose detection in a mouse model.[133] Furthermore,
Dey and co-workers[134] have designed and employed customized
gold nanoassemblies for deep tissue SORS detection have shown
improved efficiency when compared to single gold NPs at iden-
tical Au concentration and injection depths. Reports employing
an endoscopic fiber bundle for SERS detection[135] also note the
potential for on-site detection during surgery for detecting tumor
location, as well as surgery margins.
The capability of predicting depths of an inclusion (which
may be a microcalcification in a tumor or injected SERS NPs
accumulated in the tumor, etc.) by employing trained mod-
els and algorithms initially by performing signal-depth corela-
tion studies was demonstrated by the group of Matousek and
Stone.[136–138] Stemming from these initial works, they have re-
cently reported[139] the capability of predicting depths of SERS
NPs as inclusions only by measuring Raman signals from exter-
nal surfaces (SORS and TRS[140–142]) and eliminating the need of
a priori data from multiple depths, making it truly noninvasive.
Furthermore, it is not only important to be able to measure
the Raman or SERS signal from within depths, but also to be
able to fully understand the cancer cell/tissue environment. This
would be possible if there were a way tomeasure its local environ-
ment like pHor temperature. It is reported that the cell/tissue pH
is significantly different between normal and cancer cells.[143,144]
Jamieson et al. demonstrated the possibility of measuring sub-
surface pH levels using SERS (NPs) from zones within cell cul-
ture spheroids at depths of 0.5–1 mm using conventional Ra-
man microscopy.[145] Gardner et al.[146] have reported the detec-
tion of pH in the local environment of the NP noninvasively at
depth in the pH range of 2–10 and have referred to this as pH-
SESORS. Methyl benzoic acid (MBA) has been employed as the
pH-sensitive SERS tag, tagged onto 100 nm gold NPs. A change
in pH resulted in Raman (Stokes) signal shift in the benzene ring
stretching mode of MBA with pH.
An even more significant benefit of using SESORS may come
from the direct measurement of the local temperature at the
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surface of the NPs as well as that in the bulk tissue. This
would be highly beneficial in tailoring the photothermal ther-
apy for optimum outcomes. Building on an earlier work of Van
Duyne’s team demonstrating the ability to measure the temper-
ature of individual SERS NPs[147] the group of Matousek and
Stone have employed the concept of measuring the Anti-Stokes
to Stokes ratio (peak intensity) as a function of temperature
and thereby being able to predict the temperature of the Ra-
man signal generating component (matrix or NPs, etc.) nonin-
vasively at depth at its local environment, for the first time. They
have demonstrated the concept by measuring signals from Poly-
tetrafluoroethylene (PTFE) (T-SORS)[148] and SERS-tagged gold
NPs (T-SESORS) inside biological tissue.[149] Single AuNPs with
a SERS tag were used as the temperature reporters, whereas Au
nanoshells acted as heat generators (where Laser illumination
wavelength = LSPR wavelength of heat-generating nanoshells ≠
LSPR wavelength of temperature reporter AuNPs). They mea-
sured a maximum temperature rise of 20 °C with the presence
of the heat generating nanoshells, solely by measuring the ratio
of Anti-Stokes/Stokes ratio of the SERS tagged gold NPs temper-
ature reporter. Such advances in methodology development help
to advance the Raman biodiagnostics technology toward real-life
applications.
2.5.5. Others Potential Optical Techniques
Modified gold nanostructures have very recently been utilized in
short wavelength infrared (SWIR, 𝜆 = 1–2 µm) where they ben-
efit from its photoluminescence quantum yield of about 3.8% at
900 nm.[150] Alternative approaches to access signals using longer
wavelengths have been explored by theGraham and Faulds group
in utilizing chalcogenide labels to provide extreme redshifted
SERS nanotags at around 1280 nm.[151]
Another interesting technique recently reported employed the
absorption of the nanostructures (especially, gold NRs) which
would therefore reduce the transmission through the tissues
to enable detection of the regions accumulating gold NRs.
This approach is referred to as SPR enhanced optical imag-
ing/tomography (SPROI/SPROT)[152] and it was suggested that
this approach leads to improved detection when compared with
X-ray computed tomography. Gold nanostructures have also
found applications in OCT.[153] To this end, gold nanoclusters[154]
and gold nanoprisms[155] have been explored quite recently.
2.5.6. Multimodal Optical Diagnosis
As in most scenarios, it becomes evident that a single diagnos-
tic modality does not fulfil all the requirements, there has been
a significant drive toward combining multiple imaging modali-
ties by either utilizing different properties of an imaging agent or
utilizing multifunctional nanostructures to achieve multiple di-
agnosis in a single platform.Here wewill cite some relevant work
employing gold nanostructures as a multimodal optical diagnos-
tic agent. Jokerst et al.[113] demonstrated the combination of SERS
and PA imagingwith goldNRswhich are also effective photother-
mal agents. The group envisions the use of PA for characteriz-
ing the tumor shape and morphology and the use of SERS for
detecting tumor margins during surgery to check for complete
resection. Li and co-workers[156] have reported PA–Ultrasound–
X ray imaging using modified gold nanostars coated with silica
shell. Additionally, thermal imaging was studied for these con-
structs in vivo. A study by Liu et al.[102] featured the use of gold
nanostars for SERS, X-ray, and two-photon luminescence imag-
ing along with photothermal therapy. They added a fourthmodal-
ity of MRI diagnosis by attaching gadolinium to gold nanostars
and have demonstrated it in tissue phantoms and cells.[157] Many
such combinations have been suggested with variousmerits. It is
worth reflecting that multimodal approaches, that although there
are benefits frommultiple imaging techniques, a synergistic bal-
ance between them is required to make it successful in research,
technology integration, commercialization, and market adoption
phases.
2.6. Laser Exposure in Laser-Utilized Theranostics
Both diagnostic and therapeutic applications require laser light
sources that when used alone (without NPs present) should not
damage healthy tissues. This demands relatively low laser illu-
mination intensities for safety. The maximum permissible ex-
posure to which eye or skin can be accidentally exposed to light
(referred to as MPE) defined as one-tenth of the damage thresh-
old resulting from photothermal and photochemical effects, is a
way to quantify the risk of optical radiation exposure.[158] Usu-
ally, MPE is expressed in irradiance (W cm−2) as power spread
over a circular aperture. To evaluate the laser irradiance for the
purposes of the laser safety standard, one uses the actual illu-
mination area when the area is larger than the so-called lim-
iting aperture defined by the standard. For the smaller beam
areas than the limiting aperture one uses the limiting aper-
ture area itself. MPE and limiting aperture are defined in the
IEC 60825-1 depending on pulse width or exposure duration
and the spectral region for both ocular and skin exposure. For
example, for exposure time of > 10 s and a wavelength for
𝜆 = 400–1400 nm, the limiting aperture for both eye and skin
is 3.5 mm, while the MPE is 2CA W cm−2. As the empirical co-
efficient CA (also referred as correction factor) is 1 for 𝜆 = 400–
700 nm and increases to 5 for 𝜆 = 1050–1400 nm. Therefore,
the power density employed should be within 2–10 W cm−2 de-
pending on the laser line used. Moreover, for specific contact
application to nonocular tissue, the irradiance exposure level
for the specific treatment procedure may exceed the MPE, e.g.,
class 1C subject to adhering the defined conditions.[158] A clear
cost-benefit analysis and risk assessment should be undertaken
prior to considering higher exposure levels, but those much
higher than the MPE may be viable in clinical theranostics, par-
ticularly when considering the alternative of significant radia-
tion doses and the toxicity from chemotherapy for contrasting
risks.
2.7. Surface-Functionalization of Gold Nanostructures
The surface functionalization plays a crucial role, as it is this
that controls the interaction with biological components assuring
biocompatibility, longer blood-circulation time, active-targeting
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to the cells, and tumor.[159] However, this is not in the scope
of the current review, we would like to briefly summarize the
area and direct the readers to more relevant specific reviews
focusing on various aspects of biofunctionalization for appli-
cations in nanomedicine. Recent reports and reviews discuss
the role of gold nanostructure size and shape,[159–161] surface
charge,[68,81,162–164] passive targeting,[165] active targeting,[166] as
well as in vivo distribution.[167,168] It has been pointed out that
a positive surface charge like cetyltrimethylammonium bromide
(CTAB) molecules on gold NRs can have a detrimental effect by
increasing the toxicity caused to normal cells, but has demon-
strated improved uptake by tumor cells.[169] Whereas numerous
studies suggest that PEG-based polymers[171,171] have been able
to provide a neutral surface charge, as well as promote biocom-
patibility, stealthing (hiding from the immune system), and im-
proving blood circulation times, assuring better chances of up-
take by the tumor cells. Once the NPs are injected and are not
cleared out by a rapid immune response, they need to reach the
specific target locations which can be achieved by either passive
targeting or active targeting. Passive targeting utilizes the EPR
effect where the nanostructures enter the leaky blood vessels of
the tumor via EPR and is not released out of the tumor due to
the enhanced retention properties of the tumors. This phenom-
ena has been discussed in Section 3.[160,165] Active targeting of tu-
mors requires surface functionalization of gold nanostructures
with complementary ligands to those over-expressed in tumor
cells. Typically, antibodies, DNAhave been employed, whereas re-
cent aptamers, microRNAs and macrophages are also being uti-
lized for this purpose.[160,165,166,168,172–174] It is important to note
that the targeting ligands should be on the outer corona of the
nanostructures, making their binding sites available to the tar-
get along with the stealth component, but additionally should
not compromise the effectiveness of the theranostics of the
nanostructures.
3. Toxic Potential, Cellular Uptake, and
Biodistribution of Gold Nanostructures
AuNPs have gained much deserved recognition and attention in
the field of disease management, especially during the past two
decades.[175] At the same time, the growing use of AuNPs to bet-
ter understand their potential toxicity toward healthy cells/tissues
into a living system (either at the cellular level or at the level of
the whole organism) requires noteworthy concentration to vali-
date their use to solve real-world clinical problems.[176] Around
85–90% of cancers form in epithelial cells, those that line or-
gans and interact most with the ingested toxins and the envi-
ronment. Healthy epithelial cells are attached to the basal mem-
brane by tight junctions which form a continuous belt around
the circumference of each cell.[177] NPs can cross cellular mem-
branes via two distinct pathways: the transcellular pathways and
paracellular pathways.[178] Tight junctions regulate the paracel-
lular exchange of small ions and molecules between cells based
on their shape and size; in contrast, cell surface receptors stim-
ulate intracellular passage of ions, which is mainly mediated by
ligand binding and enzyme/protein interaction.[179] NPs have a
tendency to enter injured or diseased cells because of their loose
vasculature—this effect is known as EPR effect and is mainly
exploited for the accumulation of NPs in tumors.[180] Despite
recent advancements in targeted nanoformulations, the consid-
eration of off-target toxic impacts, and metabolism in cellular,
endosomal, and lysosomal conditions of AuNPs remain largely
unknown. The toxicology patterns among different structures
of gold nanostructures make their direct comparison unreli-
able, which is the result of considerably different physiochemi-
cal structures of their bulk and engineered counterparts.[181] Fur-
thermore, their cell/tissue-dependent clearance and cellular up-
take differ between AuNPs of different size, shape, compositions,
and surface charge.[182] However, current knowledge on the toxi-
cological implications and bioavailability of AuNPs hasmajor un-
certainties surrounding the fate and behavior of AuNPs in living
systems.[183] Recently available literature reports conflicting re-
sults on the toxicology of AuNPs because of the variety of avail-
able preparationmethods, functionalization routes, exposure en-
vironments/conditions, administration routes, and assessments
criteria. Another cause of apparently conflicting results is the
variability of used assays for toxicity, cell culture, animal model,
dosing parameters, and toxicity evaluation at acute, subacute,
chronic, and subchronic levels.[180,184]
Although pristine gold is generally considered as biologically
inert, chemically stable, biocompatible, and nontoxic,[185] con-
siderable unwanted toxic effects of AuNPs arise from their vari-
able synthesis routes, size, shape, surface charge, surface conju-
gates, exposure environments, and administration routes, which
are described in Sections 3.1–3.3. Furthermore, there is consid-
erable variance in the ability of AuNPs to interact with cell sur-
face membrane, their cellular uptake and localization with re-
gard to surface modification, coating, size, and shape. Under-
standing the mechanism of cellular uptake of functionalized and
coated AuNPs require characterization prior to their interaction
with cells and organs. Coating of AuNPs with CTAB has been
widely studied.[169] CTAB is a cationic micellar surfactant. CTAB-
coated AuNPs maintain stable dispersions in aqueous solutions
if prepared under correct concentrations and ratios. It has also
been reported that the higher concentrations of CTAB induces
high levels of toxicity.[169] Cellular uptake is significantly impor-
tant for specific and selective targeting of tumors. Nonspecific cel-
lular uptake of AuNPs can induce collateral damages to healthy
cells when photothermal treatments are applied. Therefore, the
removal of CTAB or such coating agents needs to be ensured
in order to achieve specific and selective delivery of NPs to dis-
eased cells.[186] Recent in vitro and in vivo toxic effects of surface
coated and pristine AuNPs have been described and compared in
Table 2.
3.1. Impact of Particle Size and Shape
The key parameter determining physiochemical properties of
AuNPs is their size, which strongly influences the in vitro
and in vivo behavior of the theranostic platform. The geomet-
ric effects of their clusters and their size order constitute cru-
cial parameters which control their biodistribution, cellular up-
take, endocytosis effectiveness, and clearance sites and clear-
ance rates.[187] It has been reported that pristine surfaces of NPs
with a diameter less than 100 nm may be able to enter cells,[182]
while similar pristine NPs smaller than 40 nm in diameter may
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Table 2. In vitro and in vivo toxicity of AuNPs.
Nanoparticles/
composites
Size Surface coating Dosage rate and
exposure time
Model
(cells/animals)
Comments on toxicity (effect on cells, organs,
tissues/cell viability)
References
Nanospheres 2 nm — 0.38–3 × 10−6 m;
1, 2.5, 6, 24 h
COS-1 Cationic particles are moderately toxic, whereas
anionic particles are nontoxic facilitated by their
strong electrostatic attraction to the negatively
charged bilayer
[229]
Nanorods 4 nm Chitosan on the
surface
50 µg mL−1, 24 h Mice Improved in vitro cellular uptake and minimal toxic
effects were observed
[230]
Bifunctional
Au/Ni NRs
20 µm long and
170 nm in
diameter
— 44 mg mL−1
4 h
HEK293 Reduced risk of cytotoxicity and immunogenicity. [231]
Nanospheres 3.5 ± 0.7 nm — 10, 25, 50, and
100 × 10−6 m
24, 48, and 72 h
RAW264.7 Au NPs are not cytotoxic, reduce the production of
reactive oxygen and nitrite species, and do not
elicit secretion of proinflammatory cytokines
TNF-𝛼 and IL1-𝛽, making them suitable
candidates for nanomedicine.
[232]
Nanospheres 2, 10, 25, 40, 50,
70, 80, and
90 nm
Herceptin physical
adsorption
10 µg mL−1
3 h
SK-BR-3, SNB-19,
and HeLa cells
Gold and silver NPs coated with antibodies can
regulate the process of membrane receptor
internalization
[233]
Nanoshperes 50 and 100 nm Tiopronin 1 nmol L−1
3–24 h
MCF-7 Optimal smaller size for NPs that maximizes their
effective accumulation in tumor tissue.
[234]
Nanospheres 4, 12, and 17 nm L-cysteine 10 × 10−9 m
3 h
HeLa Both the uptake and unbinding force values are
dependent upon the size of gold NPs.
[235]
Nanorods CTAB, PEG-SH 0.01–0.5 × 10−3 m
24 h: In vitro
(0.5–0.9 × 10−3 m in
vivo)
0.5, 3, 6, 12, 24, and
72 h: In vivo
HeLa/mice PEG-modified gold NPs showed a nearly neutral
surface and had little cytotoxicity in vitro.
Following intravenous injection into mice, 54%
of injected PEG-modified gold NPs were found in
blood at 0.5 h after intravenous injection,
whereas most of gold was detected in the liver in
the case of original gold NRs stabilized with
CTAB.
[236]
Nanostars 110 10 nm GNS SiO2/Au 10 mg g−1
4 h, 1, 4, 7, 14, 21,
28 d
Mice IV; The mass of gold in the tissue samples ranged from
our determination limit (about 70 pg) to a few
micrograms.
[237]
Nanowires 0.58, 1.8, 4.5,
8.6 nm_X
200 nm
Thiols with amino,
alkyl, or carboxyl
end groups,
serum
103–106
particles mL−1,
24 h
NIH 3T3 Internalized nanowires with high aspect ratios are
more toxic to cells than nanowires with low
aspect ratios.
[238]
Nanoclusters 0.8, 1.2, 1.4, 1.8,
CG-15
Triphenylphosphine 1–10 000 × 10−6 m
6, 12, 18, 24 h
HeLa
Sk-Mel-28
L929
J774A1
Gold particles 15 nm in size and Tauredon (gold
thiomalate) are nontoxic at up to 60-fold and
100-fold higher concentrations, respectively. The
cellular response is size-dependent, in that
1.4 nm particles cause predominantly rapid cell
death by necrosis within 12 h while closely related
particles 1.2 nm in diameter effect predominantly
programmed cell death by apoptosis.
[194]
Nanoclsuters 1.4 nm — Mice: 57 mg,
Rat: 285 mg
Mice: 2, 4, 24 h
Rat: 3, 7, 10 d
Mice, Rat clusters reach a polydentate ligand sphere that
increases the kinetic stability by orders of
magnitude
[195]
Nanoparticles 12.5 nm — IP; 40, 200,
400mg kg−1 day−1
8 d
Mice AuNPs are able to cross the blood–brain barrier
and accumulate in the neural tissue. Importantly,
no evidence of toxicity was observed in any of the
diverse studies performed, including survival,
behavior, animal weight, organ morphology,
blood biochemistry and tissue histology.
[239]
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Figure 9. Microscopic images of HeLa (A–F) and J774A1 cells (G–L) treated with Au nanostructures. A–F) HeLa cells were treated with gold nanoclusters
over 0, 1, or 12 h time. Cells were fixed, stained, and seen with an optical microscope (A,C,E) and with and scanning electron microscope (B,D,F). G–
L) J774A1 macrophages were treated for 1 h and imaged using an optical microscope. AuNPs of 15 nm diameter stained the endocytic compartment of
the cells black sparing the nucleus (K). Cytotoxicity of AuNPs against four cell lines (HeLa, SK-Mel-28, L929, and J774A1). M) HeLa cells were seeded at
2000 cells per well and were treated with AuNPs for 48 h and MTT tests were carried out for the evaluation of cell viability. N) IC50 values of Au 1.4MS
were lowest across all cell lines and that AuNPs of smaller or larger size were progressively less cytotoxic, revealing a size dependent cytotoxicity. Adapted
with permission.[194] Copyright 2007, Wiley.
approach the cellular nuclei.[187] NPs smaller than 35 nm in diam-
eter can reach the brain by crossing the blood–brain barrier, while
NPs in diameter less than ≈10 nm are excreted from the body
via renal filtration.[188] Therefore, the targeted delivery of gold
nanostructures in the tumor rely on size and surface functional-
ization/coating, which in turn can facilitate optimum theranos-
tic activity along with minimum side-effects and toxicity toward
healthy cells/tissues.[182] The extent of potential entry and clear-
ance pathways ofNPs can be changed/directed by using function-
alizing/coating agents which affect the penetration/transport of
NPs to cell membrane. Considerable work has been carried out
to investigate the particle-shape and surface functionalization-
dependent accumulation and delivery of gold nanostructures and
their corresponding toxicological effects on different in vitro and
in vivo test models.
AuNPs have long been considered to be nontoxic.[189–191] How-
ever, various cytotoxic effects have been described in a size and
shape-dependent manner. The potential causes of toxicity of
AuNPs are the release of cytotoxic ions/radicals, and transloca-
tion across the cell membrane into mitochondria. Most impor-
tantly, internalization of NPs into cells, the modification of cellu-
lar signaling pathways, and destruction of cells/cell membrane
can be other sources of toxicity.[192] Cellular uptake of AuNPs is
greatly influenced by nonspecific adsorption of proteins from the
serum onto the surface of NPs, which can increase their attach-
ment to the cell membrane and may induce receptor-mediated
endocytosis of AuNPs.[193] Pan et al.[194] reported cytotoxicity of
a series of AuNPs ranging in size from 0.8 to 15 nm against
SK-Mel-28, HeLa human cervix carcinoma, L929 mouse fibrob-
lasts, and J774A1 mouse macrophages and observed that cel-
lular uptake of AuNPs was directly dependent on particle size.
NPs ranging from 1 to 2 nm in diameter were highly toxic,
while both smaller and larger NPs were nontoxic. NPs of size
1.4 nm induced cell death by necrosis, while NPs of size 1.2 nm
caused programmed cell death by apoptosis. Size-dependent tox-
icity of AuNPs is illustrated in Figure 9. In another study, Tsoli
et al.[195,196] reported the toxicity of bare Au55 clusters (isomers
of a 55-atom gold cluster) of 1.4 nm (roughly the size of DNA)
revealed strong interaction between NPs and grooves of DNA
showing good biocompatibility and reduced toxicity. Ma et al.[197]
Adv. Sci. 2020, 1903441 1903441 (16 of 28) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
Figure 10. Induction of LC3 puncta by AuNP treatment. A) Formation of cyan fluorescent protein (CFP)-tagged LC3 (LC3-CFP) (pseudocolored as green)
in CFP-LC3 normal rat kidney (NRK) cells treated for 24 h with 1 × 10−9 m AuNPs. Left, confocal image; right, bright-field image (scale bar, 10 µm). B)
Statistical analysis of the number of autophagosomes per cell after 24 h of treatment. C) Conversion of LC3 from the cytoplasmic form (LC-I) to the
autophagosome-associated form (LC3-II). Adapted with permission.[197] Copyright 2011, American Chemical Society.
found that AuNPs of 10, 25, and 50 nm in diameter were uptaken
by normal rat kidney cells via endocytosis in a size-dependent
manner, which is likely related to the accumulation of NPs in
lysosomes resulting in lysosome degradation via alkalinization
of endocytic essentials. AuNPs induced accumulation of LC3-
positive punctuate structures when treated with normal rat kid-
ney (NRK) cells which stably expresses cyan fluorescent protein
(CFP)-tagged LC3 (LC3-CFP) (see Figure 10). In another study,
Coradeghini et al.[198] established that AuNPs with diameter of 5
exhibited toxicity in Balb/3T3 mouse fibroblasts with decrease in
cell viability from 47.0% to 36.6%, 13.6%, and 6.3% at the ex-
posure time of 2, 24, and 72 h, respectively. Toxicity was only
observed for 5 nm NPs at concentration ≥ 50 × 10−6 m leading
to their internalization within intracellular endosomal compart-
ments.
Particle diameter and surface charge are key factors determin-
ing uptake of NPs into cells. For example,Him et al.[199] described
the administration of negatively chargedAuNPs ranging from1.4
to 200 nm in diameter and positively charged 2.8 nm in diame-
ter into rats. Accumulation of negatively charged 1.4 and 200 nm
sized AuNPs in the liver increased from 50% to 99%, respectively.
While positively charged 2.8 nm NPs led to considerably dissim-
ilar accumulations in several organs in comparison to negatively
charged NPs of similar size.
The shape of AuNP affects its surface area, its surface motion,
surface plasmon shift, surface energy, ligand length, and binding
distance, which in turn affects its deposition, translocation, dis-
tribution, binding energies,membrane binding energies, uptake,
fate, and bioavailability in cells, tissues, and organs.[61,200–202] Fig-
ure 11 shows that cellular uptake of rod-shapedNPs occurs slowly
as compared to spherical-shapedNPs. It is likely that the different
levels of internalization of NRs and nanospheres are influenced
by their shape and surface morphology. In another study, Zhang
et al.[203] presented the biodistribution of PEG-coated AuNPs in
mice, which did not cause toxicity. Specifically, 5–10 and 30 nm
AuNPs accumulated in the liver and spleen of mice, respec-
tively, while 60 nm NPs aggregated preferentially in the blood
cells.
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Figure 11. Cellular uptake kinetics of AuNPs. A) Cellular uptake of AuNPs (14, 50, and 74 nm) as a function of incubation time. B) Dependence of cellular
uptake of AuNPs as a function of concentration. C) Comparison of uptake of rod-shaped NPs and spherical shaped NPs (with aspect ratio 1:3 and 1:5),
D,E) the transmission electron microscopy images of rod-shaped NPs (D—1:3, E—1:5) internalized within Hela cells. Adapted with permission.[202]
Copyright 2006, American Chemical Society.
3.2. Impact of Surface Chemistry (Surface Functionalization)
The exterior surface of AuNPs can be functionalized and modi-
fied with small biomolecules, peptides, ligands, antibodies, and
their fragments and nucleic acid to produce specific targeting
and biocompatibility of AuNPs for therapeutic, diagnostic, and
drug delivery applications.[204–206] However, the role of such func-
tionalization alterations play in determining the cellular toxic-
ity of AuNPs is still not well understood. Therefore, it is un-
doubtedly important to evaluate the relationship between func-
tionalization/bioconjugation and cellular uptake/toxicity. Hauck
et al.[207] revealed that use of polyelectrolyte as functionalizing
agent can be used to improve the uptake of gold NRs to HeLa
cells by modifying the surface chemistry of NPs using polyelec-
trolyte. The cell viability measured in most of the experimental
parameters were higher than 90% even at high concentrations.
The expression levels of oxidative stress, such as heat-shock pro-
tein or protein activity did not exhibit up- or down-regulation fol-
lowing rod-like AuNPs, which reveals that functionalizedNPs did
not induce noticeable toxicity.
Little attention has been paid on the effect of functionaliza-
tion/bioconjugation of AuNPs on the excretion and exocytosis
of AuNPs when they leave macrophages. Recently, Oh et al.[208]
showed that the bare and functionalized AuNPs mediate their
exocytosis patterns in macrophages. Cationic NPs were found
to be retained in the cells, while PEGylated NPs are likely to
be transferred in the cytoplasm, which in turn clear the NPs
due to the interactions of the NPs with intracellular proteins,
trafficking, and signaling pathways.[208] Figure 12 shows the exo-
cytosis of serum-coated AuNPs in macrophages with size ranges
of 10 A), 20 B), and 40 nm C). Chandran et al.[209] examined the
effects of bare and protein/corona functionalized AuNPs ranging
from 40 to 80 nm in diameter on corona composition and its ul-
timate effect on cellular uptake, toxicity, and gene expression re-
sponses in human umbilical vein endothelial cells. The findings
suggested that the cellular uptake of bare NPs was reduced as
a result of plasma corona formation. AuNPs are rapidly covered
by a selective group of biomolecules when they enter a biological
environment and form a corona due to the negatively charged
AuNP and positively charged proteins. Corona formation alters
the physical and chemical properties of NPs, which in turn can
cause aggregation via electrostatic interaction. Consequently, ag-
gregation affects the ability of NPs to enter target cells. The neg-
atively charged surface of AuNPs potentially bind with positively
charged extracellular proteins, which in turn reduces their ability
to be up taken by cells, while positively charged AuNPs were eas-
ily transported into cells due to the electrostatic interaction with
negatively charged cell membrane. This type of interaction of
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Figure 12. Exocytosis of serum-coated AuNPs in macrophages. A–C) Exocytosis rate of serum-coated AuNPs with size ranges of 10 (A), 20 (B), and
40 nm (C) in macrophages when treated NPs for 6, 24, and 48 h. Adapted with permission.[208] Copyright 2014, American Chemical Society.
NPswith cellmembranes can break the cellmembrane. Based on
the results discussed earlier, it can conclude that surface charge,
the interaction of NPs with proteins and the cell membrane play
a critical role in cellular localization and internalization.[199]
Therefore, surfacemodification of AuNPswith appropriate lig-
ands and concentrations proved to greatly affect the extra- and
intracellular fates of NPs.
3.3. NPs Administration Routes
Biodistribution, cellular uptake, internalization, accumulation,
and clearance of NPs clearly depends on administration route
in addition to particle size and shape.[201] It has been demon-
strated that AuNPs smaller than 5–15 nm have more target cel-
lular uptake than larger NPs of 50–100 or above.[207,209] Liver
and spleen are the main organs of living systems which have
shown increased accumulation of NPs with the increase in AuNP
diameter.[210] AuNPs have been found to have long blood circula-
tion times when their diameter increased.
Moreover, in vivo studies demonstrated that the administra-
tion route impacts the toxic effects in living systems. There are
a variety of administration routes available for the introduction
of NPs to the living systems, such as oral, intravenous, intra-
tumor, oral, intraperitoneal, and tail vein. Fan et al.[211] exam-
ined the effect of three administration routes, including oral,
intraperitoneal, and tail vein injection, on toxicity of AuNPs of
13.5 nm, revealing that oral and intraperitoneal injections caused
the highest toxicity, while tail vein injections showed the mini-
mal toxicity, which suggested that tail vein injections could po-
tentially be an appropriate route for targeted AuNPs. Tail vein
and oral administration impact most negatively on body weight
particularly after 6 and 12 days, respectively, when compared to
the control. Selection of administration route may change the
time required to reach the target, side effects, enzyme activity
based on nutritional status, and dilution of NPs. Because dif-
ferent types and sizes of NPs generate different actions when
given by different administrations routes. The underlying mech-
anisms involved in the effects of administration routes largely
remains unknown. Jong et al.[212] evaluated the biodistribution
of AuNPs (of 10, 50, 100 m and 250 nm in diameter) in intra-
venously injected rats suggesting the size-dependent distribution
of NPs. This study revealed that most NPs were found in the liver
and spleen, while the smallest 10 nm NPs were detected in the
blood, liver, and spleen. It has also been found that macrophages
were found to take AuNPs from the tissue fluid, transfer them
into the veins and then be transported to digestive organs for
clearance.[210] The shape-dependent biodistribution of AuNPs,
into themain digestive organs in zebra fish, showed a high abun-
dance of immune cells in the gallbladder (Figure 13A), pancreas,
and/or liver (Figure 13B). Nanospheres were transported to the
liver while nanourchins were predominantly found in the gall-
bladder. A macrophage loaded with AuNPs can be seen in the
tissue (confirmed by the fluorescent signal). AuNPs thereafter
were transported to the liver or spleen to be cleared from the
body.
AuNPs with controlled size, shape, composition, and structure
for their selective delivery to target sites raise important safety
constraints for application in cancer nanotheranostics. Despite
recent developments in the synthesis of gold nanostructures, a
complete elucidation of the mechanisms of AuNP cellular local-
ization, biodistribution, interplay between surface functionality,
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Figure 13. A) Images of fluorescent neutrophils and macrophages in ze-
brafish embryos after exposure to gold nanourchins. The inset is provid-
ing further details using 2 ×magnification. B) Images of fluorescent neu-
trophils and macrophages in zebrafish embryos after exposure to gold
nanobipyramids. The inset is providing further details using 6 × magni-
fication. Adapted with permission.[210] Copyright 2019, Taylor & Francis.
biological interactions, and their interaction with microenviron-
mental fluid is still a major challenge. In cancer nanotheranos-
tics, the key driver is selective delivery and retention of NPs by
tuning the physicochemical properties of NPs in enhancing ther-
anostic efficacy while remaining nontoxic toward healthy sur-
rounding tissues. Based on nanomedicine approaches, the bio-
logical fate of NPs depends on three factors; first, physicochem-
ical features of NPs including size, shape, surface charge, light-
triggered effects, and functionalization/bioconjugation; second,
biological factors, such as microenvironmental fluid, extracellu-
lar proteins, redox signaling molecules, and cellular activation;
and third, experimental factors, such as temperature (incubation
and hyperthermia) and pH of media. These issues have already
been discussed in detail in several excellent reviews.[60,61,213–215]
The internalization of AuNPs is more likely to occur via
endocytosis, which leads to engulfment of extracellular fluid
and NPs via plasma membrane ruffling followed by membrane
wrapping of NPs and cellular uptake.[216] The other process
involved in the transport of NPs into cells is direct diffusion
via cellular membranes. There are five main types of endo-
cytosis: phagocytosis, clathrin-mediated endocytosis, caveolin-
mediated endocytosis, clathrin/caveolae-independent endocyto-
sis, and micropinocytosis.[217] The process of phagocytosis is me-
diated by the binding of receptors present in the membranes of
phagocytes. Pinocytosis involves the internalization of NPs via
small pinocytic vesicles. The abundance of caveolae (a type of
lipid raft, and are small invaginations of the plasma membrane)
in cells impacts the potential of NPs for caveolae-mediated en-
docytosis, while a clathrin-binding protein attached to proteins
at membranes mediates the formation of clathrin-coated vesi-
cles, which help transport NPs into cells.[218] Direct transloca-
tion or endocytosis-mediated entry of AuNPs through cell mem-
branes results in the disruption of the lipid bilayer integrity,
which usually results in cellular toxicity. Endocytosis is mainly
considered the major process involved in the entry pathways of
NPs. Few other processes have also been demonstrated, such
as passive pathways (diffusion), disruption of lipid bilayers, and
nanoscale hole formation, and microinjection/electroporation
techniques.[219] The effects of other key factors including com-
position, size, shape, surface charge, surface functionalization,
and surface hydrophobicity/hydrophilicity, and their interactions
with cells have been discussed earlier in this section.
The notable cellular fate/transcellular trafficking features, cel-
lular uptake, and cellular localization of AuNPs have mainly
been revealed by imaging and chemical analysis tools. These
techniques include scanning and transmission electron mi-
croscopies, atomic force microscopy, scanning tunneling mi-
croscopy, flow cytometry, Raman spectroscopy, photoacoustic
microscopy, photoablation ICP-MS, dark-field microscopy, and
super-resolution fluorescence microscopy. These approaches
provide fundamentally derived experimental evidence capable of
describing specific spatial precision at nanoscale and localization
of NPs to analyze the binding site distribution of NPs at the cellu-
lar level, as well as specific binding and molecular tagging. Each
technique has its own merits and disadvantages to achieve spe-
cific biomolecular information from samples.
AuNPs, being a noble metal, displays specific optical proper-
ties which can be used as sensing elements with excellent stabil-
ity of Raman tags, since it is easy to prepare and provides favor-
able light scattering characteristics. Coherent anti-Stokes Raman
scattering has recently been used for the cellular localization and
imaging of uptake of NPs.[220–223] In another study, SERS tags
have been used to image the distribution of NPs.[215] Therefore,
Raman scattering provides key insights into the microscopic lo-
calization of NPs at intracellular levels which can potentially be
used for photothermal nanotheranostics.[225–228]
4. In Vitro and In Vivo Examples of Light-Mediated
Theranostics: Photothermal Therapy with Optical
Diagnosis Techniques
Current clinical diagnosis relies heavily on histopathology of
biopsies (excised tissues), which is time and labor consum-
ing, inherently subjective and often misinterpreted for hetero-
geneous tumors, and limited in multiplexed detection of mul-
tiple biomarkers in biopsies. More importantly, in vivo early
stage diagnosis (without undergoing biopsies) and diagnostic
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image guided operations for precision cancer removal are not
currently a reality. These have been the key driving factors for re-
searchers to develop a diagnostic technique that can cater for the
above needs. Furthermore, the possibility of diagnosis and ther-
apy combined into one platform “theranostics” not only allows
for early-stage diagnosis, image-guided operation, and therapy,
but also therapeutic monitoring allowing personalizedmedicine.
Based upon the previous sections of this review it is clear that
light-mediated gold nanostructure theranostics has the potential
to become a powerful clinical tool. To that end, we will discuss
here some interesting recent research focusing on gold nanos-
tructures, as the primary agent demonstrating theranostics with
both optical diagnosis and PTT therapy. Although there has been
a multitude of work undertaken either in the area of preparing
gold nanostructures, using them for therapy or detection, there
has been comparatively limitedwork featuring in vitro and in vivo
applications of gold nanostructures for both.
To date, X-ray andNIRfluorescence imaging coupledwith PTT
have been studied less than Raman SERS and PA. Gold NRs with
X-ray imaging chemo-PTT in vitro.[240] Tian et al. report the X-
ray absorption coefficient which suggests that the attenuation of
PEG-amine coated gold nanostars was 3.6-fold higher than that of
the commercial CT contrast agent iodixanol at the same concen-
tration of 25 mg L−1.[241] They also demonstrated light-induced
cell death, i.e., PTT.
NIR fluorescence has also been employed in combination
with PTT. For example, gold nanorod modified with custom-
synthesized acymmetris cyanine was reported for stimuli-
responsive NIR on/off fluorescence imaging. The acymmetris
cyanine in its base neutral form is nonfluorescent, whereas,
in acidic condition, the N protonates and changes in structure
which exhibits fluorescence. This was then employed as a pH-
responsive nanorod probe for fluorescence imaging and light
(808 nm) triggered photothermal therapy.[242] Among the multi-
modal approaches, typically a technique with high spatial resolu-
tion or tissue depth penetration and relatively low sensitivity (like,
X-ray, PA) has been synergistically combined with highly sensi-
tive and specific techniques otherwise having low spatial resolu-
tion or depth penetration (like NIR fluorescence, SERS etc.). MRI
is a nonoptical imaging technique with relatively high spatial res-
olution (mm) in soft tissue which has been often complemented
with other imaging techniques bymodifying gold structures with
iron oxide or gadolinium, etc., in improve the diagnostic efficacy
of these core–shell NPs.[71,102,243–245] Below, we discuss in detail
the applications of PTT with SERS or with PA, as there has been
growing interest in the field recent.
Some interesting studies demonstrate the use of different gold
nanostructures for SERS optical diagnosis coupled with PTT.
Chemo-drug cisplatin-loaded gap-enhanced Raman tags have
been reported by Zhang et al.[246] suggesting that 0.1 × 10−9 m
concentration and 3 W cm−2, 808 nm laser illumination condi-
tions resulted in 100% cell death as compared to 20% cell death
without laser irradiation, i.e., without PTT. It was demonstrated
that the SKOV3 ovarian cancer cells are most effected by the pho-
tothermal effect rather than the chemotherapeutic effect.
Further in vivo intraoperative Raman-guided chemo-
photothermal therapy has been demonstrated by Zhang and
co-workers[246] for advanced ovarian cancers with disseminated
microtumors. This suggests the benefits of combining SERS
diagnosis and PTT into one platform of designed gold nanostruc-
tures to target cancer theranostics. Multiplexing, an important
aspect, has been reported by Bhatia and co-workers[130,247] who
used gold nanostars for SERS mapping of ex vivo tumor, as
well as for in vivo multiplexed SERS diagnosis. They utilize
PD1 and EGFR targeted nanostars for the MDA-MB-231 breast
cancer cell line employing 170 µgmL−1 functionalized nanostars
and advocate that they can control cell death specifically at the
laser-irradiated zone.
It is understood that any small molecule (like optical
tags/labels, etc.) when leaching out into the cell environment can
cause an increase in cell toxicity, but on the other hand, suffi-
ciently high concentration of such labels are required to be able
to visualize or image them in in vivo conditions. Therefore, there
has been a huge drive toward functionalizing gold nanostruc-
tures to provide biocompatibility. Polyethylene glycol-based poly-
mers are the first choice andmuch of it has been discussed in the
cell toxicity section. To this end, polydopamine has also found use
and has been reported[248] to provide near-100% cell viability for
gold NRs-coated with SERS tag pMBA, further coated with poly-
dopamine (in concentration ranges of 1–200 µg mL−1 of gold), as
opposed to dramatically decreased cell viability from 90% to 15%
for gold NRs coated only with pMBA. An increase by 5–70 °C af-
ter 5 min of NIR laser irradiation was shown in the pure nanos-
tructure colloid. These structures were then demonstrated to be
useful for both SERS detection and PTT using the same laser.
Nanostars (≈40–70 nm) have become popular for SERS-PTT
theranostics applications in various reports.[101,249] Bhatia and co-
workers[104,250,251] have made elaborate contributions in utilizing
gold nanostructures especially gold NRs[122,252] for SERS diagno-
sis, as well as PTT. Folic acid functionalized gold nanobipyramids
with 2-naphthaleinthiol as the SERS tag has been reported for
SERS diagnosis and PTT of MCF7 breast cancer cell line both
for in vitro and in vivo studies.[253] Hybrid gold nanostructures,
such as silica-coated SERS labeled gold NRs[254,255] have also been
investigated.
Song and co-workers[108] suggest that by tailoring a redox ac-
tive polymer nanoparticle, porous branched gold nanoshell struc-
tures can be prepared, which has benefits in remote laser tar-
geted drug release utilizing the photothermal properties of the
gold nanostructure and bimodal optical detection of SERS and
PA imaging. Carbon-based nanomaterials, such as carbon nan-
otube and reduced graphene oxide with light absorption wave-
length from UV to NIR region and photothermal conversion
through nonradiative decay have also been explored in conjunc-
tion with gold nanostructures. Gold nanoshell coated onto car-
bon nanotube rings has been employed as a multimodal diag-
nostic agent for SERS-PA imaging, as well as PTT.[256] Graphene
oxide wrapped gold nanords[257] serve as SERS-chemo PTT ther-
anostic agent. Dox loaded onto the nanostructures provides addi-
tional pH responsive drug release and SERS behavior, thus pro-
viding a way to determine whether the Dox-loaded nanostruc-
tures have been engulfed by a tumor cell which is generally acidic
in the environment. Another report uses an elaborate construct
of reduced graphene oxide sheets with embedded gold NPs in
their nanoholes, creating SERS hot-spots, labeled with Raman
tags. Targeting EGFR lung cancer cells (A549) they report high
photothermal efficiency with a power density (0.5 W cm−2 of
808 nm NIR laser for 5 min) as a result of synergistic effect by
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conjugated AuNPs and nanosheets employed at a concentration
of 100 µg mL−1.[258] Gold nanostructures have also found appli-
cations for PTT therapy, in addition to, bimodal diagnosis, for ex-
ample, with magnetic iron oxide-gold nanostructures where the
iron oxide supports MRI providing wide area spatial scan for tu-
mor and gold nanostructure supported SERS imaging aids in de-
termining the tumor margins with higher accuracy.[164,249,259]
Multispectral optoacoustic tomography (MSOT)[260,261] has
provided PA imaging with potential to become a clinical possi-
bility. NIR absorbing gold NRs have found immense applications
in MSOT-PA imaging and superseded the traditional use of NIR
absorbing dyes.[262] Gold NRs functionalized with PEG/PEI poly-
mer were successfully employed to provide an in vitro PTT ef-
fect on 293T-GFP cells incubated with PEI-NRs with 5.0 µg per
well and irradiated for 10 min with laser (808 nm, 1 W cm−2)
and resulted in significant cell death.[263] In vivo temperature
rises of ≈30 °C was reported for similar laser irradiation as used
for in vitro studies. Micro-RNA bound gold NRs have been re-
ported as both PA and NIR fluorescence agents by incorporating
a fluorescent tag onto the gold NRs via RNA hybridization.[264]
The fluorescence signals in MCF-7 breast carcinoma and HeLa
cervical carcinoma cells treated with the above nanostructures
were reported to be enhanced 7- and 4.5-fold, respectively, com-
pared with nonamplified system and a temperature rise of about
22 °C. Furthermore, goldNRs coatedwith silica shell are excellent
candidates for photoacoustic imaging. Xu and co-workers report
such structures PA imaging, as well as combined chemo PTT
therapy.[265] Nanovesicles of semiconducting polymer-plasmonic
gold nanostructures[266] provides a unique way to enhance the
ultrasound and PA optical imaging properties, as well as the
PTT properties, thanks to the nanovesicle structure promoting
plasmonic coupling enhancements. Doxorubicin (Dox)-loaded
nanopores in the silica shell aided chemo drug release utiliz-
ing laser irradiation and PTT effect of gold NRs. They suggested
10 mg mL−1 of the above NPs showed significant improvement
as compared to chemo or PTT alone. The passively targeted NPs
provided a temperature rise of ≈60 °C and about 4 times relative
PA signal enhancement.
Gold NPs embedded in graphene sheets have also been uti-
lized for PA-PTT theranostics. Additionally, NIR fluorescence
imaging with excitation/emission: 670/690 nm could aid in
achieving a multimodal platform. SCC7 tumor-bearing mice
were subjected to exposure time of 10 min with 808 nm laser
at 0.75 W cm−2 which resulted in ≈16 °C temperature rise
and higher PA signals than control group.[267] Their study also
demonstrates that PA imaging provided better spatial resolu-
tion than NIR fluorescence imaging. The study reported by Yan
et al.[268] also supports the claim that graphene oxide-gold nanos-
tructures demonstrate significant enhancement in PA imaging
and reports a NIR fluorescence-PA imaging and PDT-PTT ther-
apy multimodal approach.
X-ray CT-PA, Fluorescence-PA bimodal diagnostics have been
exploited with gold nanostructures. You et al.[269] report the use
of hollow gold nanoshells as PA, X-ray CT, and PTT agent, along
with multimodal imaging comprising of NIR fluorescence agent
via Indocyanine green dye and MRI with gadolinium incorpo-
rated into the hollow gold nanoshells. Similarly, hollow gold
NRs[270] with optimized aspect ratio also find applications as PA–
X-ray CT–PTT theranostic agent. Such hollow NRs were synthe-
sized by a Se-doping Te nanorod-templated method with the as-
sistance of L-cysteine. In another report, gold nanoplates are em-
ployed for PA–X-ray CT imaging along with PTT in lung can-
cer cell lines.[271] They prepared anti-EGFR peptide-conjugated
PEGylated triangular gold nanoplates of dimensions ≈80 nm
and employed them in vivo PA–CT imaging and a temperature
rise of ≈21 °C. Laser mediated assembly formation of gold NPs
and further employing them for PA imaging with a combina-
tion of 405 nm and NIR laser, has been achieved by Cheng and
co-workers.[272] DNA-mediated gold nanorod assemblies have
proven to be better candidates than the gold NRs itself in cellu-
lar uptake, PA imaging, as well as temperature rise of 15 °C due
to PTT effects.[273] This thereby drives the interest in developing
and utilizing gold nanoassemblies in theranostics.
Table 3 lists some of the examples of in vivo theranostic appli-
cations employing gold nanostructures for optical diagnosis with
PTT therapy. It is apparent that sub-100 nm gold nanostructures
have found their way to in vivo experiments, especially in mouse
models. These are usually grafted with tumors from human or
mice cells, with breast cancer cell type being the most studied.
5. Translational Aspects of Gold Nanoclusters as a
Theranostic Agent
Cancer nanotheranostics represents a major recent advance-
ment in diagnosing and treating cancer and is now considered
a paradigm shift in the field of experimental medicine. Several
gold nanostructures have shown tremendous effects in animal
models for Raman scattering and plasmonic photothermal ther-
apy. One distinctive feature of AuNPs in cancer theranostics is
the improvement of the efficacy with minimal toxicities. Another
feature is enabling noninvasive imaging of diseased tissues by
traceable NPs. Despite their high success in experimental mod-
els, studies of durable/long-term clinical responses are very lim-
ited. Therefore, there is a need to establish the efficacy and excre-
tion pathways of AuNPs in longer term models and eventually
human trails. It would be of great value to bioengineer a method
that can predict treatment response and that will enable optimiza-
tion of the likelihood of therapeutic success and reduce the risks
and expense of unnecessary treatment.
AuNPs are now routinely used within in vitro devices, as di-
agnostic tools in the clinic: such as pregnancy test kits contain-
ing antibody-conjugated AuNPs, which are applied for the colori-
metric detection of human chorionic gonadotropin in urine and
allowing a naked-eye readout. AuNPs undergo plasmonic colori-
metric change on detecting a change in hormone levels of urine.
Awide range of NP-based detectionmethods, including biomark-
ers in blood, urine, and saliva, are also in clinical use.
AuNPs are in the translation phase to in vivo applicationwithin
a number of labs around the world. In an ongoing clinical trial,
Naomi Halas from the Rice University and Steven Canfield from
the McGovern Medical School at University of Texas are using
AuNPs to treat prostate cancer.[275] Their recent findings so far
are promising, and side effects are relatively minimal.[276] They
have used gold–silica nanoshells (with a diameter of 150 nm,
8.28 µg g−1 (range, 1.15–33.12 µg g−1) of concentration of NPs
and dose of 7.5 mL kg−1) used in this procedure comprise of tiny
layers of silica glass in spherical shapes with a thin layer of gold
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Table 3. Comparison of in vivo applications of combined optical diagnosis and PTT.
Theranostic agent NP size Diagnosis In vivo
model
Cancer tumor cell type Remarks Refs.
Nanostars 50–70 nm Raman SERS Mice Human Breast cancer
MDA-MB-231
Multiplexed detection [123]
Gold NPs embedded
in graphene sheets
15 nm NPs formed on
graphene sheets
PA imaging and NIR
fluorescence
Mice SCC7 tumor Spatial resolution achieved was
better in PA imaging
[267]
Triangular gold
nanoplates
≈80 nm PA and X-ray CT
imaging
Mice HCC827 tumor Temperature rise of 21 °C was
noted
[271]
Gold–Silver
nanotriangles
≈80 nm PA and Raman
imaging
Mice MGC 803 Hybrid gold–silver nanostructure [274]
Gold NRs Sub-100 nm NR placed
on DNA origami of
≈100 nm each side
PA imaging Mice 4T1-fLuc mouse
breast-cancer cells
DNA-coated gold NRs were found
to be more effective than
uncoated ones
[273]
Nano bipyramids Length 117 nm and
width ≈36 nm
Raman SERS Mice Human breast cancer
cells MCF-7
Folic acid-targeting employed [253]
coating on each sphere. These NPs have successfully reached tar-
get sites and been stimulated by laser light (NIR (810 ± 10 nm)
was delivered continuously for 3 min at a power level subabla-
tive in the absence of NPs. Laser power was delivered via a dual
lumen, water-cooled catheter), which kills the cancer cells selec-
tively. These core–shell NPs were cleared through the liver, while
some remain sequestered in the liver and spleen with no notice-
able side effects. 16 men aged 58–79 with low- to intermediate-
grade prostate cancer were involved in this clinical trial. The
treatment was successful in 87.5% of lesions treated at 1 year of
follow-up. This clinical work may be able to address unanswered
questions for the clinical translation of gold nanotechnology cou-
pled with optical diagnostics and treatment procedures.
Numerous preclinical studies have shown the potential of
AuNPs for the diagnosis and treatment of cancer, but the clinical
translation of AuNP in the diagnosis/treatment modalities is still
in its infancy, since long-term chronic toxic impact of NPs, off-
target toxicity, metabolism, neurotoxicity, immunotoxicity, fate
of protein-based nanoformulations, clearance/excretion mecha-
nism, lack of specific target knowledge, disease detection capabil-
ities, and the use of diagnosis to assist or guide NPs-based ther-
apy procedures remains unexplored.
There is a lot of controversy on the localization, toxicity, bio-
compatibility, circulation, biodistribution, and clearance of NPs
in literature to date: all these parameters give conflicting results
based on the diversity of experimental protocols (such as size,
shape, functionalization method, animal model, administration
route). However, these theranostic procedures may need to be
standardized in meeting product quality assessments, NPs char-
acterization, safety evaluations, and experimental protocols of the
in vitro and in vivo work.[17,277–279] Significant variations noted
among individual tumors and therapeutic responses from one
patient to another and temperature patterns between individu-
als are critical in introducing new approaches and procedures in
clinical settings. These make it hard to interpret the results of
small studies and that more statistical power or robust protocols
are needed to understand these variations. Therefore, the most
important translational barriers need to be considered during lab-
oratory experiments to make the technology safe and effective by
determining the selection, as well as the delivery conundrum of
right diagnostic/treatment option, right cell, and right dose, with
minimal collateral damages.
Specifically, the translation of photothermal theranostics could
be challenging because of the considerable variations of temper-
ature in tumors, the magnitude and duration of temperature ap-
plied, nonuniform distribution of the temperature within dis-
eased tissue, cooling effects of surrounding tissues/blood ves-
sels, location of the tumor, distance from the light source, density
of the tumor, vascularization of the tissue, and other uncontrol-
lable factors. Therefore, a standardized experimental procedure
should be established to enable comparative evaluations of each
approach. The use of the newly developed T-SESORS/T-SORS
approaches outlined above make a direct noninvasive measure
of the temperature using the Raman signal induced by the PTT
laser. This could have a profound effect on clinical utility and pre-
cision of this approach.
Furthermore, the scale-up of cost-effective, reproducible AuNP
production, including their complex geometries/morphologies
and multilayered biocojugated is another translational barrier.
However, research advances in this field are currently beingmade
by numerous academic researchers outlined here. Therefore,
proposed programmes of work should be aligned with clinical
endpoints. This requires better coordination between academic
researchers and clinicians/clinical investigators. With the tran-
sition of AuNPs from the benchtop to the bedside, we need to
address unanswerable clinical questions about the fundamental
problems in translating this “golden age” technology into the
“postmodern age.”
6. Conclusions and Future Perspectives
There has been a growing trend in developing various novel
engineered AuNPs for integrating both optical diagnostics and
photothermal therapy within a single procedure. Advancing gold
nanostructure-based Raman nanotheranostics may be pivotal for
translating from in vitro therapeutics and detection tomore com-
plex biological systems in vivo within clinical settings.
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Furthermore, there have been major recent advances in sur-
face enhanced spatially offset Raman spectroscopy (SESORS) to
provide optical imaging and lesion localization combined with
PTT and direct optical feedback to provide accurate in vivo tem-
perature and pH monitoring. We have reviewed evidence for
this growing consensus and have highlighted the combination
of two modalities (diagnosis and treatment) in a single, efficient,
cost-effective, and targeted procedure. This review also provides
significant advancements by addressing the challenges to find-
ing new techniques of functionalizing AuNPs with molecules
that can facilitate effective binding, formation of a corona, clear-
ance, biocompatibility, biodistribution, and toxicity. It has also
addressed the unmet clinical need and translational barrier of
immediate and effective nonsurgical cancer detection and diag-
nosis with high specificity and sensitivity using gold nanostruc-
tures in a single, effective, nonsurgical procedure. Gold nanos-
tructures have widely been explored for medicinal applications
but still there is a long delay in the translation of these (NPs) to
be commercialized for routine in vivo light-triggered treatment
options.
Raman-based multiplexed theranostic systems can elucidate
the complexity of disease function and provide for linked diag-
nostic and therapeutic procedures. Raman scatteringmay revolu-
tionize theranostic procedures including monitoring of traffick-
ing at cellular/subcellular levels, cellular localization, reassess-
ment of EPR, and may provide key insights into transcyto-
sis, exosomal transport, and hyperthermia control in achieving
clinically-relevant diagnostic aided and image-based therapeutic
responses.
Many newNPs have been developed and tested for cancer ther-
anostics with overall therapeutic success rates in cell culture and
animal models remaining very high. However, there are many
barriers in translating and adopting them into clinical settings
such as: i) limited understanding of long-term toxic effects of
AuNPs, ii) nonspecific biodistribution profiles, short plasma cir-
culation time, and rapid systemic elimination, iii) relatively low
accumulation at the target site, and iv) fate of NPs in the blood-
stream of a living system and in the cytoplasm of the cell, as well
as in the media in which cells grow (a mixture of electrolytes,
proteins, nutrients, and metabolites). In these regards, Raman
spectroscopic approaches could potentially play an important role
in detecting nano–bio interactions at cellular/subcellular levels.
There is, however, considerable room for further basic science ad-
vancing the understanding of biological interactions with AuNP
on the nanoscale, novel NP engineering, Raman signal recovery,
NP localization, dosimetry, and real-time monitoring of hyper-
thermia, all requiring a concerted effort for successful translation
and adoption of clinical tools utilizing Raman nanotheranostics.
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